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October 16, 2018 
 
Dr. Kenneth Aldape 
Editor-in-Chief, Neuro-Oncology 
 
RE: Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial 
ependymoma, N-O-D-18-00629 
 
Dear Dr. Aldape: 
 
7KDQN\RXIRUUHYLHZLQJRXUPDQXVFULSW³Craniospinal irradiation as part of re-irradiation for 
children with recurrent intracranial ependymoma´ 
 
Please find enclosed a letter with point-by-point responses WRDOOUHYLHZHUV¶FRPPHQWV&RSLHVof 
the revised manuscript, with changes tracked, have been uploaded to the electronic manuscript 
system. 
 
Please let us know if there are any questions. We appreciate your ongoing review and hope you 
will consider our manuscript for publication. 
 
 
 
Derek S. Tsang, MD MSc FRCPC  Louise Murray, PhD 
. 
&RYHU/HWWHU
Reviewer comments are in italics. 
Author responses are bolded. 
Yellow highlight denotes changed text. 
Green highlight denotes existing text, for emphasis only. 
 
Reviewer #1: General Comments 
 
A second course of radiation therapy is increasingly recognized as a viable option to salvage 
children with recurrent ependymoma after prior surgery and radiation therapy; however, there 
are many unanswered questions about the appropriate radiation dose and volume for these 
patients as well as a lack of information about long-term disease control and functional 
outcomes. The present study seeks to address these important questions and provide new or 
supportive information about re-irradiation for ependymoma. The analysis is extensive. As in 
any retrospective series that includes children with ependymoma, the number of patients is small 
and the number of clinical subgroups is large - the analysis in this study is extensive. The study 
includes 22 patients with infratentorial ependymoma and 9 patients with supratentorial 
ependymoma: two very distinct groups/diseases that should be considered separately or a 
comment should be added.  
 
We agree that IT and ST ependymoma differ in underlying biology. To highlight this point, 
we have made the following modifications: 
Abstract / Conclusions: Re-irradiation with CSI is a safe and effective treatment for 
children with locally recurrent ependymoma and improves disease control as 
compared with focal re-irradiation, with the benefit most apparent for those with 
infratentorial primary tumours. 
 
)LJXUHRUGHU7KHJUDSKVIRU³DOOSDWLHQWV´LH,7DQG67FRPELQHGKDYHEHHQ
moved last, while those for the IT and ST primaries, separately, were moved first. 
 
We also highlight the importance of interpreting study findings while considering primary 
tumour location in the following existing and modified text: 
,PSRUWDQFHRIWKH6WXG\«We found that CSI for locally recurrent ependymoma 
offered a freedom-from-progression benefit, especially for those with infratentorial 
tumours. 
 
Results: all results are reported both combined and separately for IT and ST 
tumours. 
 
Discussion, 1st paragraph: This study found that CSI was associated with a 
statistically significant improvement in FFP, particularly in the setting of local 
recurrence of infratentorial (posterior fossa) ependymoma. There was also a trend 
to improved OS with use of CSI-RT2 for locally recurrent infratentorial 
ependymoma. 
 
Discussion, last paragraph: Furthermore, infratentorial and supratentorial 
ependymoma are two different disease entities with different molecular alterations; 
5HVSRQVHWR5HYLHZHUV
as such, they should be considered separately.[17] To date, re-irradiation studies 
have not handled ependymoma in this manner. Although our subgroup analysis of 
infratentorial tumours demonstrated a FFP benefit to CSI-RT2, greater patient 
numbers are needed to validate these findings. There were insufficient patient 
numbers to rigorously evaluate the role of CSI-RT2 in locally recurrent 
supratentorial tumours, neither in those with local or disseminated recurrence; 
these are subgroups deserving of further study. There were also insufficient events 
to perform a multivariable analysis. 
 
Amongst the infratentorial patients, at the time of initial treatment, only 8 underwent GTR with 
the remaining 9 treated with NTR and 5 with GTR. It's interesting that 6 of the NTR patients and 
5 of the STR patients would undergo GTR after local progression and prior to RT2. This should 
probably be explained. 
 
Thank you for pointing this out. We reassessed the extent of resection for all cases for 
whom STR or NTR was achieved at first surgery, using operative reports and post-
operative imaging. 
 
Among the patients without GTR at first surgery and local recurrence: 
 Pre-RT2 surgery 
Pre-RT1 surgery None STR NTR GTR Total 
STR  4  4* 8 
NTR 2   6* 8 
Total 2 4 0 10 16 
*More complete resection was achieved with repeat surgery 
 
Therefore, there are 10 patients for whom a more radical resection was achieved with 2nd 
surgery. The reasons for each are as follows: 
 
a) First surgery was done outside our institution: n = 5; patient 2 (Argentina), patient 3 
(London, Canada), patient 22 (Spain), patient 23 (Saudi Arabia), patient 26 
(Germany) 
b) First surgery showed involvement of a critical structure that was subsequently 
dissected out at second surgery: n = 4; patient 1, patient 4, patient 12, patient 28 
c) Quick section pathology at first surgery VXJJHVWHG³ORZJUDGH DVWURF\WRPD´VR
surgeon decided not to perform radical surgery: n = 1; patient 14 
 
We have added the following text to Results, 2nd paragraph: 
Of 16 patients without GTR at first surgery and subsequent local recurrence, 10 
achieved GTR at subsequent surgery for recurrence because: a) first surgery was 
done by a different surgeon at an outside institution (n = 5); b) more aggressive 
surgery near critical structures was performed at recurrence (n = 4); c) revised 
pathologic diagnosis from glioma to ependymoma after first surgery (n = 1). 
 
Finally, we found one patient (patient 8) that was erroneously coded as having NTR at first 
surgery but actually received a STR. Tables 1 and e1 have been corrected. 
 Specific Comments - There are 4 distinct clinical groups and key findings that should be 
considered for focus: 
 
Infratentorial primary site, local failure and treatment with focal RT2 or CSI-RT2 - the thrust of 
this study is that CSI is the preferred treatment for patients with local failure. This manuscript 
centers on 4 patients with infratentorial patients treated with CSI-RT2 and compares them to 12 
patients treated with focal RT2. Three of the 4 CSI-RT2 patients were treated with GTR prior to 
RT2, 3 of the 4 received CSI doses of 23.4Gy, and only 2 were followed longer after RT2 than 
their interval from RT1 to recurrence. What is the rationale for a CSI dose of 23.4Gy for 
ependymoma? 
 
There was a tendency to use reduced-dose CSI for younger patients and for patients with 
local recurrence. Numbers are too small to draw definitive conclusions about which CSI 
dose is most suitable for patients with locally recurrent ependymoma. However, to better 
describe the patients that we treated, we have added a new Table e1 to the supplementary 
material so that readers can observe: 
a) Younger patients in our series tended to receive lower CSI doses; 
b) About half of locally recurrent patients received reduced-dose CSI. 
 
Table e1. CSI dose by post-RT1 pattern of failure, with patient age at start of RT2 
CSI dose Distant failure Local failure Total 
 n Ages (y) n Ages (y)  
23.4 Gy 1 6.5 4 5.3-8.4 5 
36 Gy 8  3  11 
 
The existing text in Materials and Methods briefly explain the rationale for reduced-dose 
CSI. We have clarified this phrase as follows: 
23.4-36 Gy were delivered to the whole neuraxis in 1.8 Gy daily fractions, with lower 
doses reserved for selected younger patients (age 7-8 or under, see Table e1). 
 
The existing and modified text also elucidates the age range by CSI dose: 
The median age at RT2 was 6.4 years (range, 5.3-8.4) and 13.2 years (range, 7.3-
22.3) amongst those who received 23.4 Gy (n = 4) and 36 Gy (n = 3) CSI for locally 
recurrent disease, respectively (p = 0.057). 
 
 How was the overlap of the CSI-RT2 and boost treatment (54Gy) managed at the level of the 
previously exposed spinal cord, brainstem, or other critical structures beyond the information 
included in the manuscript? 
 
There were 16 patients who received CSI as part of RT2. Fifteen patients had available 
dosimetry (one received RT2 at an outside institution). We verified the distribution for 
each patient; all 15 received comprehensive neuraxis craniospinal irradiation without 
shielding to any in-field critical structure. 
 
This detail is clarified in the modified Materials and Methods, subsection Radiotherapy: 
 No doses >100% were permitted in brainstem, optics or cord for RT2. CSI included 
all structures in the brain and spinal cord, without shielding applied to optic 
structures, brainstem, or cervical spinal cord. All re-irradiated patients received 
real-time image guidance with daily cone beam computed tomography. 
 
Infratentorial primary site, dissemination and treatment with CSI-RT2 - there were 6 patients 
included in this group. Four of 6 have experienced progression after CSI-RT2 and 1 patient has 
been followed for only 1.1 months. Any explanation beyond that provided in the manuscript 
about the poor results which are at odds with other series? For example, was the disease 
especially extensive at RT2 or did relapse occur in shielded sites? 
 
No shielding was applied (see previous comment). 
 
Disease was not particularly extensive after recurrence; three had 1 lesion at failure, two at 
2 lesions at failure, and one had 4 lesions at failure. 
 
All six of these patients (patients 15, 16, 17, 18, 20, 30) had anaplastic ependymoma at 
diagnosis. The recurrent pathology was not consistently graded in our institution. However, 
in the recent report from St. Jude (IJROBP, volume 100, issue 2, 2018, 
doi:10.1016/j.ijrobp.2017.10.002), anaplastic histology at recurrence was associated with a 
hazard ratio of 5.1 for death (p = 0.001). Anaplastic histology was also a strong prognostic 
factor for PFS and OS in de novo ependymoma enrolled on ACNS0121 (unpublished; 
SUHVHQWHGDW&KLOGUHQ¶V2QFRORJ\*URXSPHHWLQJ2FWREHU-5, 2018). This factor may have 
contributed to the poor outcome in this subgroup. 
 
Four patients experienced subsequent disseminated recurrence (patients 15, 17, 18, 20). Of 
these, three had negative prognostic factors: 
- Patient 17: The re-irradiated lesion was large (3.5 cm) and was biopsied only 
- Patient 18: Initial recurrence consisted of local and distant failure; this is a known 
group with poor prognosis (see previously cited paper from the St. Jude group) 
- Patient 20: One had 4 lesions at recurrence; subsequent disseminated recurrence is 
not surprising 
 
We have clarified some of these points in the revised text: 
First, in the present study, those with disseminated relapse after RT1 had poor 
outcomes, with no long-term survivors, despite treatment with CSI as part of RT2. 
This is in contrast to the data from St. Jude9 and from France20 which showed that 
those with distant failures treated with CSI did well. In the present study, the 
interval between RT1-to-failure was 1.4 years among those with disseminated 
relapse, comparable to the French data (1.2 years for all patients) and the St. Jude 
cohort (1.8 years for all patients). In our dataset, those with combined local and 
distant failure, a recognized poor prognostic factor9, were categorized together in 
one ³GLVVHPLQDWHG´JURXSGXHWRWKHVPDOOQXPEHUVRISDWLHQWVZLWKFRPELQHG
failures; this may have negatively affected the overall outcome of this cohort. 
Second, all but one of these patients had anaplastic histology at diagnosis, which 
may be challenging to control, even with RT2.9 There can also be a referral bias 
among studies in the literature, whereby patients with a better prognostic profile 
may be included, resulting in improved outcomes reported by other research groups 
as compared to our present study which included an unselected group of patients. 
Overall, longer-term follow-up is needed to better elucidate the true nature of this 
high-risk subgroup of children. 
 
Supratentorial primary site, local failure and treatment with focal RT2 or CSI-RT2 - there were 
5 total with the group (excluding the patient treated with SRS) divided between CSI-RT2 (n=3) 
and focal RT2 (n=2). The focal group comprised those with residual disease at the time of RT2 - 
both patients progressed after RT2 and died. The CSI-RT2 group comprised a better resection 
group (3/3 GTR) with only one patient progressing locally only 3.7 months after RT1 and with 
dissemination after RT2. Based on the numbers it is difficult to make any conclusions. 
 
We agree that the numbers are small. We were unable to draw any firm conclusions in the 
supratentorial group of tumours. See next comment for manuscript text edits. 
 
Supratentorial primary site, dissemination and treatment with CSI-RT2 - there were 3 patients 
all of whom progressed at died. Are the investigators prepared to make the statement that ST 
patients with any component of dissemination after RT1 cannot be salvaged? 
 
Numbers are too small to make this determination. All of our cases with known molecular 
pathology had RELA fused tumours which are known to have a poor prognosis. 
 
To highlight the points raised by the reviewer, we have modified the text in Discussion as 
follows: 
There were insufficient patient numbers to rigorously evaluate the role of CSI-RT2 in 
locally recurrent supratentorial tumours, neither in those with local or disseminated 
recurrence; these are subgroups deserving of further study. 
 
Random and Minor Points 
 
* What would be the youngest age for which CSI be administered? 
 
Age 5 at start of RT2, see new Table e1 (copied above in this letter, too). 
 
* One patients [sic]  received 55.8Gy RT1 
 
I am unclear why this patient was not treated to 59.4 Gy. This child received RT1 at 4 
years. The target extended to the foramen magnum but did not involve the cervical spinal 
canal. 
The delivered dose was confirmed using electronic radiation records, the radiation record-
and-verify system (MosaiQ), and the dose-distribution: the patient indeed got focal, tumour 
bed RT1 to 55.8 Gy. Pathology was also verified as ependymoma (grade 3) at both 
diagnosis and recurrence (not medulloblastoma). 
 
* One of the local relapse patients received CSI prior to 2012 (95.6 months follow-up) 
 Patient 14 had atypical cells in CSF at the time of local ependymoma recurrence in 2009, 
but no malignant cells. This patient was the subject of thorough discussion amongst 
treating physicians and the final decision was to offer 36 Gy CSI followed by focal 
recurrent tumour bed boost. 
 
The Results text has been clarified to identify the patient number of the individual who had 
atypical CSF cytology. 
 
7 patients with local relapse received CSI-RT2, with a further boost to the local site 
of recurrence. One patient amongst these seven (patient 14) had suspicious 
cerebrospinal fluid cytology prior to RT2 without macroscopic evidence of distant 
disease. 
 
Table e2 (listing of all patients) has been annotated to mark patient 14 as having local 
recurrence and atypical CSF. 
 
CSI re-irradiation as a treatment for locally recurrent ependymoma was not adopted as 
standard-of-care until 2012. 
 
7KH³,PSRUWDQFHRIWKH6WXG\´ZDVFODULILHGWRKLJKOLJKWWKLV 
In 2012, our institution changed practice to offer craniospinal irradiation (CSI) for 
patients with locally recurrent ependymoma, with focal re-irradiation being routine 
prior to this date. 
 
To improve readability - ways to reduce the amount of analysis, text and improve the focus of the 
manuscript would be to shorten or remove the following: 
 
* Molecular information - The abstract, introduction, methods, and discussion include 
information about the molecular profiles. It should be mentioned whether these data contributed 
to the analysis.  
 
The molecular analysis was descriptive, because there were no PF-B tumours 
(infratentorial) and all supratentorial tumours had RELA fusion. Because tissues were 
exhausted for the patients for whom the molecular test result was unknown, we did not feel 
it was be meaningful to compare those with known vs. unknown molecular status. 
Therefore, the molecular profiles are reported descriptively. Nonetheless, this is the first 
known report of the molecular profiles of recurrent ependymoma treated with re-
irradiation.  
 
The last paragraph of the discussion has been modified to note this limitation. 
It was not possible to stratify results by molecular subgroup because all the supratentorial 
tumours had RELA fusions and no infratentorial patient had PF-B pathology; therefore, 
molecular pathology was reported descriptively only. 
 
The median age of the PF-A group was 4.8 years with a range of 1.2-13.0 years. Is this what is 
expected for PF-A? 
 
Yes. In a paper published in JCO (volume 34, issue 21, page 2468, 
10.1200/JCO.2015.65.7825), the median age ranged between 2.4-4 years across sub-cohorts, 
with a range from 0-77 years. 
 
* SRS patients - Appreciating the comment that conventional fractionation is safer, what is 
the value of including the SRS patients? 
 
Although there are many other retrospective and an ongoing prospective study 
(NCT02125786) about the role of fractionated RT2 for this disease, SRS re-RT is poorly 
studied. There are some who advocate for SRS or hypofractionated re-irradiation (Kano et 
al., JNS Pediatrics 6, 417-423, 2010 and Hoffman et al., JNO 2014, 10.1007/s11060-013-1259-3 
and Waxweiler et al., PBC 2016, 10.1002/pbc.26341 and Murai et al. 2016, 10.1007/s11604-
015-0511-5 and Liu et al. PBC 2009, 10.1002/pbc.21982). In the study by Hoffman et al., six 
patients developed radiation necrosis (50% crude rate), 3 of which were symptomatic (25% 
crude rate). In our series, two patients received SRS and one developed symptomatic 
necrosis. We believe it is important to include this important detail in the present study so 
that readers can appreciate the potential adverse effects of focal SRS re-treatment. 
 
Second, we wished to avoid arbitrary removal of patients that could bias results. One of the 
important findings for our study was that CSI resulted in a disease control benefit over 
focal RT, be it fractionated or SRS. The risk of distant failure is independent of focal RT 
treatment technique. Therefore, inclusion of all cases that satisfy the study inclusion 
criteria reduces the possibility of bias. 
 
Third, Reviewer #2 commented that focal fractionated RT and SRS are not the same, and 
asked if SRS patients should be removed altogether. To determine the effect of including 
SRS cases in our cohort, we did a sensitivity analysis with SRS cases (n = 2) removed. The 
results are unchanged: Patients who received CSI RT2 for locally recurrent ependymoma 
experienced a statistically significant improvement in freedom-from-progression as 
compared to those who got focal fractionated RT. These figures are now included Figure 
e2. 
 
The text has been modified to discuss inclusion of the SRS cases, as well as the above-
mentioned sensitivity analysis. 
 
 Results: 
Because the treatment technique differs between fractionated RT2 and SRS RT2, 
analyses were repeated after excluding all children treated with a second course of 
radiation using SRS (n = 2). Results are shown in Figure e2. Use of CSI-RT2 
continued to be associated with a statistically significant FFP benefit amongst the 
entire cohort (log-rank p = 0.016) and in the subgroup of patients with infratentorial 
primary tumors (log-rank p = 0.039).  
 
* RT3 data - If RT3 impacts the value in the 17th column of Table e1 [Last follow-up 
(months from RT2)] , this value is difficult to interpret. 
 
RT3 does not affect this value. The last follow-up time was calculated using the date of 
death (for patients who died) or the last contact (for living patients). 
 
Reviewer #2: The paper is extremely well written considering the limitations of a single 
institution study and a rare disease in which patient numbers are limited. 
 
A few comments to possibly help improve the manuscript : 
 
Abstract - I would move the sentence in results about molecular characterisation to later on in 
the results section. 
 
This change has been made: 
Results: Median follow-up was 5.5 years. 23 patients had known molecular status; 
all had posterior fossa group A tumours (n = 17) or RELA-fused tumours (n = 6). Of 
9 patients with distant relapse after initial RT, 2-year freedom-from-progression 
(FFP) and overall survival (OS) were 12.5% and 62.5%, respectively. There were 22 
patients with local failure after initial RT. In these patients, use of CSI during re-RT 
was associated with improvement in 5-year FFP (83.3% with CSI vs. 15.2% with 
focal re-RT only, p = 0.030). In the subgroup of patients with infratentorial primary 
disease, CSI during re-RT also improved 5-year FFP (100% with CSI, 10.0% with 
focal re-RT only, p = 0.036). 23 patients had known molecular status; all had 
posterior fossa group A tumours (n = 17) or RELA-fused tumours (n = 6). « 
 
                I would change "no patient developed radiation necrosis following fractionated RT" - 
take out fractionated -see below about SRS patients 
 
Please see response to Reviewer 1 about inclusion/exclusion of SRS cases; a summary is 
also provided below in response to another comment by Reviewer 2. 
 
7RHQVXUHFODULW\WKHVHFWLRQ³,PSRUWDQFHRIWKLV6WXG\´ZDVDPHQded: 
No cases of radiation necrosis (in the absence of disease progression) were seen after 
fractionated re-irradiation, though patients treated with re-RT are at risk of long-
term cognitive & endocrine deficits. 
 
Main paper 
 
In the methods section- age 18 and under (I would add clarify this is at diagnosis) 
 
This point has been clarified in the Material and Methods text: 
Paediatric patients age 18 or under (at the time of initial ependymoma diagnosis) 
who were treated« 
 
We also clarified inclusion criteria: 
Eligible patients had a pathological diagnosis of intracranial ependymoma and 
received focal RT1 for localised disease at initial diagnosis. 
 
 and also whether there was a minimum time interval between RT1 and RT2 before RT2 was 
considered 
 
The shortest time interval was 0.49 years (rounded to 0.5 in Table 1 to be consistent in 
significant digits in that row). The text has been modified to highlight this: 
 Materials and Methods: 
All patients were treated with photon external beam RT. The shortest RT1-to-RT2 
time interval in the study was 6 months, with all remaining patients having at least a 
10-month gap between the two treatments to allow for potential normal tissue 
recovery. « 
 
Results: 
The median age at RT2 was 6.4 years (range, 5.3-8.4) and 13.2 years (range, 7.3-
22.3) amongst those who received 23.4 Gy (n = 4) and 36 Gy (n = 3) CSI for locally 
recurrent disease, respectively (p = 0.057). The shortest RT1-to-RT2 time interval in 
the study was 6 months, with a median interval of 23 months. 
 
 
The 2 patients who had SRS should be removed from the analysis- adding in SRS patients to this 
cohort confounds the analysis and also the message of the paper.  SRS and local fractionated 
radiotherapy are not the same treatment and furthermore the SRS patients did not have surgery 
although their recurrence was small. As stated in the discussion, outcomes for SRS in this group 
in the Merchant paper were poor and it is possible that the inclusion of the SRS patients in this 
treatment group could contribute to the results and introduce bias. 
 
Please see response to Reviewer 1 about inclusion/exclusion of SRS cases. In brief, we 
ultimately decided to include the SRS cases because they inform readers about the 
potential risks of this treatment. Inclusion of SRS cases also does not bias the CSI/focal RT 
comparison since SRS is a form of focal RT2. Nonetheless, to ensure that our results were 
robust, we performed a sensitivity analysis after excluding both SRS cases (Figure e2) and 
the study findings were unchanged. 
 
We do believe that including the SRS cases provides a greater degree of transparency 
about our results, does not bias the CSI/focal RT analysis, and provides an important piece 
of information about the potential risks of single-fraction treatment. 
 
Were all the patients treated with focal radiotherapy treated using the same type of treatment 
delivery?  
 
Out of 15 patients treated with focal RT2, 2 received SRS and 13 received modern RT 
(IMRT or VMAT). These details are now added to the revised Table 1. 
 
Was there a change from 3D conformal to IMRT or VMAT? 
 There was no use of 3DCRT for the focally irradiated patients. However, two patients who 
had distant failure after RT1 and got CSI-RT2 had 3DCRT boosts. These are now listed in 
revised Table 1. 
 
 Is it possible that better delivery of focal radiotherapy through improvements in radiation 
technology including proton therapy might improve local control with focal RT through reduced 
compromise to critical structures? 
 
No patient in our study received proton therapy. Most patients received modern, inverse-
planned RT. It is possible that use of new technologies, such as MR-guided radiotherapy, 
can ensure that no focally irradiated patient has a marginal miss. However, this is 
hypothesis-generating at the present time, and in need of further study. 
 
We did add a comment about proton CSI in response to another comment from Reviewer 2 
(see below). 
 
  This should be mentioned in the discussion as we are likely comparing older style fractionated 
local XRT possibly using 3D conformal  or step and shoot IMRT with CSI given that the initial 
XRT and also focal RT1 was delivered before 2012. 
 
We have added a comment about radiotherapy techniques to the paragraph in the 
Discussion about limitations of the study: 
Most ± though not all ± of our patients were treated with modern, inverse-planned 
radiotherapy. It is possible that more modern techniques have resulted in improved 
tumour targeting and/or better organ-at-risk sparing compared to older techniques, 
but this current dataset does not have sufficient numbers of patients treated with 
older techniques to allow such an analysis. None of the patients in this series 
received proton therapy, which may add additional benefits. Radiotherapy 
techniques, in particular the impact of protons, should therefore be the focus of 
further study. 
 
Furthermore it would be useful in the discussion to add in the potential benefits of proton 
therapy in this instance both in reducing integral dose in initial RT1 but also as a potential way 
of reducing integral dose to viscera if using for RT2 especially if re-irradiating spinal sites and 
reducing late effects. 
 
We agree with the rHYLHZHU¶VVXJJHVWLRQ7KLVKDVEHHQDGGHGWRWKH Discussion: 
There is published evidence supporting use of proton beam therapy to deliver CSI 
as definitive treatment for primary brain tumours in adults26 and children27. Proton 
CSI is associated with reduced acute toxicities26,27 as well as an expectation of 
reduced late toxicities due to dosimetric sparing of normal tissues in the torso.28-32 
Given the high rates of disease control with CSI for locally recurrent ependymoma, 
proton CSI could be considered in this setting. There is an ongoing prospective 
study (ClinicalTrials.gov identifier, NCT02125786) that allows use of proton CSI for 
recurrent ependymoma. 
 The results section should mention with respect to RT3 how many patients had focal versus CSI 
as part of RT2  
 
This has been added to the Results, subsection Third course of radiation. 
Of all eight patients, two had received prior CSI as part of RT2 (36 Gy, patients 18 
and 21). 
 
and whether any patients underwent repeat CSI as part of RT3 (even from the supplemental 
material it is difficult to make this out without manually going through each patient) 
 
Thank you for this suggestion. This has been added to the Results, subsection Third course 
of radiation. 
Three patients received whole spine RT3 followed by focal spine boosts, two 
received fractionated focal RT3, two received CSI followed by boost RT, and one 
received SRS. 
 
Also it is unclear as to how radiation necrosis was diagnosed and managed and differentiated 
from tumour recurrence - was this always pathological or were some radiological diagnoses 
made that could have been recurrence. 
 
All radiation necrosis (n = 6, most after RT3 or more) was diagnosed clinically using 
neuroimaging. Radiation necrosis tended to have a more diffusely enhancing appearance 
whereas tumour recurrence tended to be nodular. MR spectroscopy was used in half of 
these cases to help distinguish between recurrence and necrosis. Where there was 
diagnostic doubt, repeat imaging was performed to try to clarify the diagnosis. 
 
4 patients ultimately developed distant failure after local necrosis, whereas 2 patients had 
local failure after RT2. 
 
In the case of the 2 individuals with local failure: 
- Patient 6 developed necrosis 7 months after RT3, and was treated with bevacizumab 
and hyperbaric oxygen. The patient subsequently had 1.5 years of disease control 
prior to further local recurrence. The clinical picture as well as time course were 
consistent with necrosis followed by delayed tumour recurrence. 
- Patient 8 developed necrosis 2 months after RT2 (SRS), and was treated with 
steroids alone with improvement. The patient subsequently had local recurrence 2 
years later. Again, the clinical picture as well as time course were consistent with 
necrosis followed by delayed local tumour recurrence. 
 
To clarify use of neuroimaging to detect radiation necrosis, the following text was added to 
Materials and Methods: 
Post-treatment surveillance MR imaging was used to detect tumor recurrences or 
radiation necrosis. When available, MR spectroscopy was used to help differentiate 
between necrosis or recurrence. In cases of diagnostic uncertainty, short-interval 
repeat imaging was used to clarify the true diagnosis. 
 In the discussion it is mentioned that 2 patients had both RT and RN which is not uncommon and 
that RN was diagnosed and treated in one case following SRS and treated with dexamethasone. 
The diagnosis of and management of RN should be better clarified here in more detail. 
 
See previous comment for clarification regarding diagnosis of radiation necrosis. 
 
These are the patients that had necrosis, as well as their treatments: 
Patient Treatment for radiation necrosis 
1 Dexamethasone 
3 None (had tumour recurrence as well) 
6 Bevacizumab, hyperbaric oxygen 
7 Dexamethasone 
12 Observation 
24 Bevacizumab (had tumour recurrence as well) 
 
The manuscript text has been edited to include these details, as well as correction of a 
typographical error (patient 12 received RT5, rather than patient 13): 
Three other patients developed necrosis: one after RT3 (21 Gy SRS; patient 1), one 
after fractionated RT3 (36 Gy CSI followed by in-field supratentorial boost to 54 Gy 
with RT1 and RT2 overlap; patient 6), and one after a fifth course of RT (SRS, 
patient 1213). Treatments for necrosis included observation (patient 3 and 12), 
dexamethasone only (patients 1 and 7), bevacizumab (patients 6 and 24) and 
hyperbaric oxygen (patient 6). 
 
In the case of patients 3 and 24, neuroradiologist review felt that there was evidence of both 
frank radiation necrosis as well as tumour progression. Typically, these cases would be 
excluded from a count of necrosis, since we feel that radiation necrosis should be included 
only if there was no evidence of active neoplasm. However, in the interests of full 
transparency regarding all potential toxicities of re-irradiation, these cases are discussed 
descriptively in the existing Results text: 
Two patients developed tumour progression with evidence of necrosis after RT2 
(patients 3 and 24). 
 
Did the survivors who had not developed neuro-endocrine deficit all have 23.4Gy CSI rather 
than 36?  This would seem likely explanation for this result and if so should be commented on. 
 
Among the 5 who had neuroendocrine deficits, 3 received 23.4 Gy and 2 received 36 Gy. 
This is now discussed in revised text: 
Half of all surviving patients did not, or have not yet, developed neuroendocrine 
deficits; of the five who developed such deficits, 3 received 23.4 Gy CSI and 2 
received 36 Gy. 
 
To better clarify this, we have added the CSI doses to Table 4, as follows. (A truncated 
version of Table 4 is reproduced here.) 
Patient no. RT2 field Neuroendocrine deficits 
2 focal (RT3 CSI 23.4 Gy) Hypothyroidism and GH deficiency 
5 SRS None 
9 CSI 36 Gy None 
11 focal None 
13 CSI 23.4 Gy GH deficiency 
14 CSI 36 Gy Hypothyroidism and GH deficiency 
16 CSI 36 Gy Irregular menses 
26 focal None 
27 CSI 23.4 Gy None 
28 CSI 23.4 Gy GH deficiency 
 
 
Reviewer #3: Please provide a little more detail to clarify re-irradiation planning parameters.  
Was any effort made to block previously treated areas of the brain or was full dose always 
given?   
 
No structures were shielded during re-irradiation; full prescribed re-irradiation dose was 
given. This is now clarified in modified text: 
No doses >100% were permitted in brainstem, optics or cord for RT2. CSI included 
all structures in the brain and spinal cord, without shielding applied to optic 
structures, brainstem, or cervical spinal cord.  
 
You state that at re-irradiation, brainstem, cord and optic maximum doses were limited to 54 Gy.  
Was this for the 2nd course of RT only?   
 
Correct ± this is now clarified in the modified text (see below). 
 
Were there cumulative dose limits to these structures? 
 
There were no cumulative dose limits. This is now clarified in the modified text: 
Methods: 
At re-irradiation, brainstem, cord and optic doses were limited to a point maximum 
RI*\DLPLQJIRU379FRYHUDJHZLWKRIWKHRT2 prescription dose; 
no cumulative dose limits were applied. 
 
 Results: 
The mean and median combined RT1 and RT2 physical prescriptions were 106 Gy 
and 113 Gy, respectively. 
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Abstract 
Background: To The goal of this study was to evaluate outcomes in children with relapsed, 
molecularly-characterized intracranial ependymoma treated with or without craniospinal 
irradiation (CSI) as part of a course of repeat radiation therapy (re-RT). 
 
Methods: This was a retrospective cohort study of 31 children. Patients with distant relapse 
received CSI as part of re-RT. For patients with locally recurrent ependymoma, those treated 
before 2012 were re-irradiated with focal re-RT. In 2012, institutional practice changed to 
offer CSI, followed by boost re-RT to the site of resected or gross disease.  
 
Results: Median follow-up was 5.5 years. 23 patients had known molecular status; all had 
posterior fossa group A tumours (n = 17) or RELA-fused tumours (n = 6). Of 9 patients with 
distant relapse after initial RT, 2-year freedom-from-progression (FFP) and overall survival 
(OS) were 12.5% and 62.5%, respectively. There were 22 patients with local failure after 
initial RT. In these patients, use of CSI during re-RT was associated with improvement in 5-
year FFP (83.3% with CSI vs. 15.2% with focal re-RT only, p = 0.030). In the subgroup of 
patients with infratentorial primary disease, CSI during re-RT also improved 5-year FFP 
(100% with CSI, 10.0% with focal re-RT only, p = 0.036). 23 patients had known molecular 
status; all had posterior fossa group A tumours (n = 17) or RELA-fused tumours (n = 6). No 
patient developed radiation necrosis after fractionated re-RT, though almost all survivors 
required assistance throughout formal schooling. Five out of ten long-term survivors have not 
developed neuroendocrine deficits. 
 
Conclusions: Re-irradiation with CSI is a safe and effective treatment for children with 
locally recurrent ependymoma and improves disease control as compared with focal re-
irradiation, with the benefit most apparent for those with infratentorial primary tumours.  
 
Keywords (MeSH) 
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ependymoma, re-irradiation, recurrence, pediatrics 
 
Key points 
- Re-RT for recurrent ependymoma is safe & provides disease control in some patients 
- CSI re-RT improves disease control in locally recurrent ependymoma 
- No case of necrosis solely attributable to fractionated re-RT was observed 
 
Importance of the Study 
This study reports clinical and toxicity outcomes of a cohort of children treated with repeat 
irradiation for recurrent ependymoma. In 2012, our institution changed practice to offer 
craniospinal irradiation (CSI) for patients with locally recurrent ependymoma, with focal re-
irradiation being routine prior to this date. This provided an ideal before-and-after cohort to 
evaluate the role of CSI. We found that CSI for locally recurrent ependymoma offered a 
freedom-from-progression benefit, especially for those with infratentorial tumours. No cases 
of radiation necrosis (in the absence of disease progression) were seen after fractionated re-
irradiation, though patients treated with re-RT are at risk of long-term cognitive & endocrine 
deficits. Given the improved disease control seen with comprehensive neuraxis re-irradiation, 
CSI should be discussed as an option for patients with locally recurrent ependymoma. 
N-O-D-18-00629R1 
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Introduction 
Ependymoma accounts for 9% of paediatric central nervous system (CNS) tumours, with 
90% arising intra-cranially1,2. At diagnosis, patients with localised disease typically undergo a 
maximal safe resection, followed by adjuvant post-operative radiotherapy (RT1) to the 
tumour bed.3,4 Challenges arise in the setting of recurrent disease, which occurs in 
approximately 30-50% of patients.4 Maximum safe resection is appropriate, and, in the 
absence of effective systemic therapy3,5,6, a second course of radiation (RT2) may be 
undertaken which overlaps with the first.7-9 Despite traditional concerns surrounding the 
potential side effects of re-irradiating the paediatric brain to cumulative doses above what 
would usually be considered normal tissue tolerance, this has been found to be well-tolerated, 
with low rates of radiation necrosis.8,9 
 
It has previously been demonstrated that re-irradiation for children with recurrent 
ependymoma results in improved survival compared to historical controls who were not 
treated with RT2.8 In the setting of disseminated relapse, patients should receive craniospinal 
irradiation (CSI) as a component of RT2, with subsequent boost RT to sites of gross or 
resected disease. However, the optimal radiation field for localized recurrence is controversial 
and not well-defined. For localised relapse without distant dissemination, patients have been 
typically re-irradiated with focal RT2 to the recurrent tumour bed.7-9 
 
Since our institution adopted focal re-irradiation for locally recurrent ependymoma, it has 
been observed that a large proportion of patients who relapse following focal RT2 
subsequently develop distant disease elsewhere within the neuraxis. This raised the question 
as to whether CSI as part of RT2 could improve disease control as compared with focal RT2. 
Since 2012 and onward, CSI has been offered as a standard treatment in the setting of locally 
recurrent ependymoma. This change created an ideal before-and-after cohort to study the role 
of CSI for recurrent intracranial ependymoma in children. Thus, the objectives of this study 
were to evaluate freedom-from-progression (FFP) and overall survival (OS) between patients 
N-O-D-18-00629R1 
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who were treated with or without CSI as a component of RT2, in a molecularly-characterized 
study cohort. 
 
Materials and Methods 
Paediatric patients age 18 or under (at the time of initial ependymoma diagnosis) who were 
treated at the Hospital for Sick Children and Princess Margaret Cancer Centre in Toronto, 
Canada between 1999 and 2018 were retrospectively reviewed. Eligible patients had a 
pathological diagnosis of intracranial ependymoma and received focal RT1 for localised 
disease at initial diagnosis. Those who subsequently relapsed and received at least one course 
of re-irradiation were identified from neuro-oncology and radiotherapy databases. Patients 
underwent repeat surgery at recurrence, when possible. 
 
Patients with recurrence at solely the site of the original disease, within the RT1 field, were 
considered to have local relapse. Patients with relapse distant to the site of original disease 
and/or malignant cells within the CSF were considered to have disseminated disease. Those 
with synchronous local aQGGLVWDQWIDLOXUHZHUHLQFOXGHGLQWKH³GLVVHPLQDWHG´JURXSGXHWR
the small number of combined failures (n = 3). For the infratentorial tumours, molecular 
subgroup characterization was performed on initial resection specimens using a combination 
of genome wide methylation arrays 10 and H3K27me3 immunohistochemistry staining.11,12  
Two cases had tissue that could not be characterized due to weak H3K27me3 staining and 
lack of further tissue for methylation profiling. In the supratentorial tumours, a genome-wide 
methylation array was used to characterize RELA fusions.13 
 
Radiotherapy 
At the time of initial presentation (RT1), FKLOGUHQPRQWKVRUPRQWKV received 54 Gy 
or 59.4 Gy in 1.8 Gy daily fractions to the post-operative tumour bed, respectively. For 
patients who relapsed with localised disease, our institutional practice had been to offer focal 
re-irradiation (RT2) until 2011. Focal RT2 dose was adapted to RT1 dose; those who had 
N-O-D-18-00629R1 
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received RT1 59.4 Gy were treated with RT2 54 Gy, while those who had received RT1 54 
Gy were treated with RT2 59.4 Gy (Figure e1). The GTV included the recurrent, post-
operative tumour bed and all macroscopic disease with 0-1 cm CTV margin and 0-0.5 cm 
PTV margin, depending on proximity to organs at risk. Where the RT2 prescription dose was 
59.4 Gy and the PTV overlapped with brainstem, cord or optic structures, a two-phase plan 
was adopted: the PTV was treated to 54 Gy, followed by a boost treatment (5.4 Gy in 3 
fractions) with reduced margins to minimize overlap with critical structures. Two patients 
received cobalt-based stereotactic radiosurgery (SRS; 15-24 Gy) using a rigid stereotactic 
frame (Elekta AB, Sweden) for small, isolated local recurrences. 
 
From 2012 and onward, CSI as a component of RT2 (CSI-RT2) was adopted as a standard 
option for patients with isolated focal relapse (Figure e1). 23.4-36 Gy were delivered to the 
whole neuraxis in 1.8 Gy daily fractions, with lower doses reserved for selected younger 
patients (age 7-8 or under, see Table e1). Focal boosts of 54-59.4 Gy were delivered to the 
recurrent post-operative tumour bed and any residual macroscopic disease as described above. 
Similarly, patients who relapsed with disseminated disease received 36 Gy CSI, followed by 
boost RT2 to 54-59.4 Gy.  
 
All patients were treated with photon external beam RT. The shortest RT1-to-RT2 time 
interval in the study was 6 months, with all remaining patients having at least a 10-month gap 
between the two treatments to allow for potential normal tissue recovery. At re-irradiation, 
brainstem, cord and optic doses were limited to a point maximum of 54 Gy, aiming for 95% 
PTV coverage with 95% of the RT2 prescription dose; no cumulative dose limits were 
applied. No doses >100% of the prescription dose were permitted in brainstem, optics or cord 
for RT2. CSI included all structures in the brain and spinal cord, without shielding applied to 
optic structures, brainstem, or cervical spinal cord. All re-irradiated patients received real-
time image guidance with daily cone beam computed tomography. Post-treatment 
surveillance MR imaging was used to detect tumor recurrences or radiation necrosis. When 
N-O-D-18-00629R1 
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available, MR spectroscopy was used to help differentiate between necrosis or recurrence. In 
cases of diagnostic uncertainty, short-interval repeat imaging was used to clarify the true 
diagnosis. 
 
Analysis 
Clinical characteristics were reported descriptively; proportions and continuous variables 
ZHUHFRPSDUHGXVLQJ)LVKHU¶VH[DFWWHVW and the Wilcoxon rank-sum test, respectively. The 
Kaplan-Meier method was used to calculate OS and FFP (defined as time to disease 
recurrence) from the first day of RT2. Living patients were censored at last follow-up. 
Median follow-up was calculated by reversing the censoring variable in the Kaplan-Meier 
analysis for death. OS and FFP, stratified by clinicopathologic factors, were compared using 
log-rank tests. Cox regression was used to explore univariate factors associated with OS and 
FFP, and to evaluate statistical interaction between variables. Multivariable analysis was not 
performed due to the small sample size. Analyses were performed using SAS version 9.4 
(Cary, NC, USA). The study was approved by the research ethics boards of both the 
University Health Network and Hospital for Sick Children. 
 
Results 
We identified 31 patients who were re-irradiated for relapsed ependymoma. Baseline 
characteristics are summarised in Table 1, and individual patient data are listed in Table e21. 
All patients underwent surgery at initial presentation prior to RT1. For all but one patient, 
RT1 was delivered at initial presentation, and the remaining patient received surgery and 
chemotherapy initially, and RT1 at first recurrence. In total, 10 patients received 
chemotherapy at initial presentation, either to delay radiotherapy due to young age (n = 2), to 
facilitate more complete surgery (n = 5, 1 patient eventually proceeded to second surgery), as 
adjuvant therapy (n = 2), and as an alternative to radiotherapy (in the 1 patient who received 
RT1 at first relapse, chemotherapy was given at first presentation to facilitate further surgery). 
23 patients (74%) had complete molecular subgroup characterization; all the patients with 
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infratentorial tumours had group A tumours while all the supratentorial tumours had RELA 
fusions. There were no patients with posterior fossa group B tumours. 
 
Surgery was recommended to reduce the burden of disease as well as to obtain pathologic 
confirmation of recurrence prior to embarking on RT2. A majority of patients underwent 
surgery for relapsed ependymoma, with 65% achieving GTR. Of 16 patients without GTR at 
first surgery and subsequent local recurrence, 10 achieved GTR at subsequent surgery for 
recurrence because: a) first surgery was done by a different surgeon at an outside institution 
(n = 5); b) more aggressive surgery near critical structures was performed at recurrence (n = 
4); c) revised pathologic diagnosis from glioma to ependymoma after first surgery (n = 1). 
Surgery was recommended to reduce the burden of disease as well as to obtain pathologic 
confirmation of recurrence prior to embarking on RT2. Nine patients relapsed with 
macroscopic disseminated disease, including three with concurrent local relapse. Of these 
nine, six underwent tumour resection; three had more extensive recurrences; of these three, 
one underwent biopsy, and two had no surgery. 
 
Of all patients, 22 relapsed locally, without radiologic or pathologic evidence of 
dissemination. Among these children, 15 underwent focal RT2 (13 with fractionated RT2, 
and 2 using single fraction SRS). The 2 patients who received SRS for small recurrences in 
the original tumour bed did not have surgery prior to RT2. 7 patients with local relapse 
received CSI-RT2, with a further boost to the local site of recurrence. One patient amongst 
these seven (patient 14) had suspicious cerebrospinal fluid cytology prior to RT2 without 
macroscopic evidence of distant disease. There was no statistically significant difference in 
the proportion of locally recurrent patients who attained a GTR versus not before RT2, 
between the focal or CSI RT2 groups (p = 0.35). The median age at RT2 was 6.4 years 
(range, 5.3-8.4) and 13.2 years (range, 7.3-22.3) amongst those who received 23.4 Gy (n = 4) 
and 36 Gy (n = 3) CSI for locally recurrent disease, respectively (p = 0.057). The shortest 
RT1-to-RT2 time interval in the study was 6 months, with a median interval of 23 months.  
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Of all re-irradiated patients, 27 received re-irradiation at the time of first recurrence and 3 
received re-irradiation at second recurrence (with surgery and/or chemotherapy at first 
recurrence). One patient received RT at third recurrence. The mean and median combined 
RT1 and RT2 physical prescriptions were 106 Gy and 113 Gy, respectively. 
 
Survival 
Median follow-up was 65.3 months. Median FFP was 23.3 months (95% CI 13.6-43.5), with 
a 3- and 5-year FFP of 38.6% (95% CI 20.6-56.4) and 24.1% (95% CI 9.4-42.5; Figure 1). 
Because no patient died without the presence of progressive ependymoma, FFP was equal to 
progression-free survival. The median survival for the entire cohort was 53.1 months (95% CI 
28.4-94.5), with a 3- and 5-year OS of 62.8% (95% CI 41.7-78.0) and 39.9% (95% CI 20.5-
58.7). 
 
Amongst those with local failures after RT1, use of CSI-RT2 was associated with a 
statistically significant improvement in FFP. The median FFP was 26.7 months (95% CI 9.1-
43.5) in those who did not receive CSI-RT2, versus not reached for those who received CSI-
RT2 (log-rank p = 0.030, Figure 2). The 5-year FFP was 15.2% (95% CI 2.5-38.2) versus 
83.3% (95% CI 27.3-97.5) for no CSI versus CSI-RT2, respectively. However, this difference 
did not translate into a statistically significant difference in OS, with a 5-year OS of 43.1% 
(95% CI 17.9-66.2) versus 80.0% (95% CI 20.4-96.9; log-rank p = 0.23) for no CSI versus 
CSI-RT2, respectively. 
 
Among 22 patients with infratentorial (IT) ependymoma, 16 experienced local failures after 
RT1. Of those, four received CSI as part of RT2 while 12 received focal RT2. In an 
exploratory subgroup analysis of patients with IT ependymoma and local relapse, CSI-RT2 
was associated with improvement in 5-year FFP (100% [95% CI 100-100]) as compared to 
those treated with focal RT2 only (10.0% [95% CI 0.6-35.5], log-rank p = 0.036, Figure 2). 
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There may be an associated OS improvement (5-year survival of 100% [95% CI 100-100] vs. 
36.7% [95% CI 11.3-63.0], respectively) but this did not reach statistical significance (log-
rank = 0.093). 
 
Among 9 patients with supratentorial (ST) ependymoma, 6 experienced local failures after 
RT1; of these, half received CSI as part of RT2. In an exploratory subgroup analysis of 
patients with ST ependymoma and local relapse, CSI-RT2 was not associated with 
differences in FFP or OS, likely due to a small sample size (Figure 2).  
 
Because the radiation treatment technique differed between fractionated RT2 and SRS RT2, 
analyses were repeated after excluding all children treated with a second course of radiation 
using SRS (n = 2). Results are shown in Figure e2. Use of CSI-RT2 continued to be 
associated with a statistically significant FFP benefit amongst the entire cohort (log-rank p = 
0.016) and in the subgroup of patients with infratentorial primary tumors (log-rank p = 
0.039). 
 
Amongst all patients with distant failures after RT1, CSI was always given. Despite this 
treatment, there were no long-term survivors beyond 5 years. Median survival was 30.3 
months; 2-year and 4-year OS probabilities were 62.5% (95% CI 22.9-86.1) and 37.5% (95% 
CI 8.7-67.4), respectively. Median FFP was 16.6 months, with a 2-year FFP probability of 
12.5% (95% CI 0.6-42.3). 
 
Factors associated with OS and FFP are listed in Table 2. On univariate analysis, no factor 
was significantly associated with OS. There was strong trend to improved FFP with use of 
CSI for local failures after RT1. There was no interaction between use of CSI and the extent 
of surgery before RT1 (p = 0.81) or before RT2 (p = 0.64) for the FFP endpoint. Sex was 
excluded from this analysis because all patients with locally recurrent ependymoma treated 
after 2011 with CSI-RT2 were males. Few females, who have a better prognosis overall 4,14, 
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recurred after 2011; thus far, none had yet been treated with CSI for a locally recurrent 
ependymoma. 
 
The patterns of failure after RT2, stratified by type of RT1 failure and treatment received, are 
listed in Table 3. Most patients who received CSI-RT2 for local failure after RT1 did not 
recur; one patient in this group developed recurrent disease outside the RT2 boost volume 
(but within the CSI-RT2 treated volume).  
 
Toxicities and functional outcomes after RT2 
Patients who were treated with RT2 tolerated re-treatment well, with no high-grade acute 
toxicities. All patients completed the planned course of RT2 re-irradiation. 
 
One patient developed radiation necrosis attributable to RT2; patient 7 developed grade 3 
necrosis after SRS RT2 that was treated with dexamethasone alone. The patient had some 
neurologic recovery but remained ataxic and wheelchair-dependent; this individual eventually 
developed local disease progression and died. Two patients developed tumour progression 
with evidence of necrosis after RT2 (patients 3 and 24). Three other patients developed 
necrosis: one after RT3 (21 Gy SRS; patient 1), one after fractionated RT3 (36 Gy CSI 
followed by in-field supratentorial boost to 54 Gy with RT1 and RT2 overlap; patient 6), and 
one after a fifth course of RT (SRS, patient 123). Treatments for necrosis included 
observation (patient 3 and 12), dexamethasone only (patients 1 and 7), bevacizumab (patients 
6 and 24), and hyperbaric oxygen (patient 6). 
 
Functional outcomes among ten long-term survivors without evidence of active disease 
(median follow-up: 59.8 months) are listed in Table 4. Most individuals had mild or moderate 
difficulties with formalized education, requiring additional assistance in the form of an 
individualized education plan.15 Two patients ± including one who received CSI ± were able 
to enroll in a post-secondary education programme. Half of all surviving patients did not, or 
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have not yet, developed neuroendocrine deficits; of the five who developed such deficits, 3 
received 23.4 Gy CSI and 2 received 36 Gy. 
 
Third course of radiation 
Following RT2, eight patients went on to receive at least one more course of radiotherapy, 
with overlap with RT1 or RT2 in seven individuals. Three patients received whole spine RT3 
followed by focal spine boosts, two received fractionated focal RT3, two received CSI 
followed by boost RT, and one received SRS. Of all eight patients, two had received prior 
CSI as part of RT2 (36 Gy, patients 18 and 21). Individual cases are discussed in detail in the 
Supplementary Material. Median survival after a third course of radiotherapy (RT3) was 19.3 
months, and median FFP was 8.8 months. In patient 2, RT3 led to long-term survival (>5 
years from RT3); this individual was treated with focal RT2 but suffered distant failure; RT3 
consisting of 23.4 Gy CSI and boost to all sites of disease led to long-term disease control.  
 
Discussion 
We present 31 paediatric patients treated with a repeat course of radiation for relapsed 
intracranial ependymoma. Most patients had NTR or GTR prior to RT2. Our institutional 
practice to systematically offer CSI to patients with recurrent local disease from 2012 
onwards created an ideal quasi-experimental before-and-after cohort to study the role of CSI 
in treatment of locally recurrent intracranial ependymoma. This study found that CSI was 
associated with a statistically significant improvement in FFP, particularly in the setting of 
local recurrence of infratentorial (posterior fossa) ependymoma. There was also a trend to 
improved OS with use of CSI-RT2 for locally recurrent infratentorial ependymoma. 
 
A majority of patients (n = 23) had successful molecular subgroup characterization. This is 
the first known study of recurrent intracranial ependymoma to include molecular and 
methylation subgroup information. It is well-known that posterior fossa group A and RELA-
fused tumours carry a worse prognosis 13,16; thus, it is not surprising that our cohort comprised 
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exclusively of these tumours. Gain of chromosome 1q is also known as a negative prognostic 
factor 17,18; in a large cohort of patients treated at St. Jude &KLOGUHQ¶V5HVHDUFK+RVSLWDO, 
patients with recurrent intracranial ependymoma treated with repeat RT were enriched for 
both 1q gain and RELA fusions.9 
 
Prior studies 
Merchant et al. from St. Jude were the first to report detailed outcomes for paediatric patients 
re-irradiated for ependymoma7 with a recent update by Tsang et al.9 There were 46 locally 
recurrent patients who received focal RT2 and 10 patients who received CSI as part of RT2. 
In a multivariable analysis, use of CSI for locally recurrent disease was not associated with a 
statistically significant improvement in OS or FFP. CSI did eliminate disseminated failures 
after RT2, whereas 44% of recurrences after focal RT2 were distant-only failures. Patients 
selected for RT2-CSI with locally recurrent ependymoma in this study likely had attributes of 
more aggressive disease. 
 
A survey of the management of 108 children with relapsed ependymoma was reported by 
Messahel et al.19. 69% of these children had local-only relapse. In a comparison of all 
patients, including those with distant recurrence, children who received CSI at relapse (n = 
10) had improved survival compared to those irradiated focally at relapse (n = 17) and those 
who did not receive radiotherapy at relapse (n = 45). Only 14 of these 27 irradiated patients 
had RT as re-irradiation; nonetheless, as with this current study, CSI as a component of 
salvage therapy was associated with improved outcomes. 
 
Few other studies have reported specifically upon the use of CSI for locally recurrent 
ependymoma. In a series by Lobon et al., 15 patients with local recurrences were treated with 
focal irradiation, with a crude disease control rate of 40%.20 Distant failures represented about 
half of post-RT2 recurrences. In a study by Eaton et al., 11 patients with locally recurrent 
ependymoma were re-treated with focal proton therapy.21 In this subgroup, five experienced 
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further local failures after RT2 without any cases of distant failures. Outcomes for up to 12 
re-irradiated patients are included within other series.22-24 For example, in the study by Combs 
et al., 3-year progression-free and overall survival for seven patients focally re-irradiated for 
local recurrence were 64% and 83%, respectively, following a median dose of 36 Gy (range 
20-60 Gy) in 1.8-2.0 Gy fractions.23 Survival outcomes were comparable to those observed in 
this current study for focally re-irradiated patients. 
 
Radiation necrosis 
Some caution may be required if using a hypofractionated schedule for re-irradiation in young 
patients: Hoffman et al. described hypofractionated RT2 in 11 paediatric patients with locally 
recurrent ependymoma using 24 Gy in 3 fractions with excellent local control (3-year LC 
89%).25 However, radiation necrosis occurred in 45% of re-irradiated patients (n = 5), two of 
whom required treatment with bevacizumab.25 Merchant et al. reported low rates of disease 
control and high rates of necrosis (crude rate 83%) in 6 patients re-irradiated with SRS.7 In 
the present study, there were two individuals who developed evidence of tumour progression 
synchronously with necrosis after RT2. The remaining four instances of necrosis occurred 
after SRS or irradiation after RT2. Therefore, our contemporary practice is to deliver RT2 
using daily fractions of 1.8 Gy per day. 
 
To our knowledge, this is one of three largest series examining re-irradiation in children with 
relapsed ependymoma. It is also the only known study to specifically evaluate CSI as part of 
RT2 in the setting of isolated focal relapse, and to report the molecular subgrouping of 
recurrent pediatric ependymoma. However, there are some important differences between 
these data and the cases previously reported in the literature. 
 
First, in the present study, those with disseminated relapse after RT1 had poor outcomes, with 
no long-term survivors, despite treatment with CSI as part of RT2. This is in contrast to the 
data from St. Jude9 and from France20 which showed that those with distant failures treated 
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with CSI did well. In the present study, the interval between RT1-to-failure was 1.4 years 
among those with disseminated relapse, comparable to the French data (1.2 years for all 
patients) and the St. Jude cohort (1.8 years for all patients). In our dataset, those with 
combined local and distant failure, a recognized poor prognostic factor9,  were categorized 
together iQRQH³GLVVHPLQDWHG´JURXSGXHWRWKHVPDOOQXPEHUVRISDWLHQWVZLWKFRPELQHG
failures; this may have negatively affected the overall outcome of this cohort. Second, all but 
one of these patients had anaplastic histology at diagnosis, which may be challenging to 
control, even with RT2.9 There can also be a referral bias among studies in the literature, 
whereby patients with a better prognostic profile may be included, resulting in improved 
outcomes reported by other research groups as compared to our present study which included 
an unselected group of patients. Overall, longer-term follow-up is needed to better elucidate 
the true nature of this high-risk subgroup of children. 
 
This study has some limitations. Although associated with a large FFP benefit, the number of 
patients with local recurrence after RT1 treated with CSI-RT2 was small (n = 7). Detailed 
tests of neuropsychological function after RT2 were only available for four patients and are 
not reported here due to small numbers. Furthermore, infratentorial and supratentorial 
ependymoma are two different disease entities with different molecular alterations; as such, 
they should be considered separately.17 To date, re-irradiation studies have not handled 
ependymoma in this manner. Although our subgroup analysis of infratentorial tumours 
demonstrated a FFP benefit to CSI-RT2, greater patient numbers are needed to validate these 
findings. There were insufficient patient numbers to rigorously evaluate the role of CSI-RT2 
in supratentorial tumours, neither in those with local or disseminated recurrence; these are 
subgroups deserving of further study. There were also insufficient events to perform a 
multivariable analysis. Testing for 1q chromosome gain was not performed. It was not 
possible to stratify results by molecular subgroup because all the supratentorial tumours had 
RELA fusions and no infratentorial patient had PF-B pathology; therefore, molecular 
pathology was reported descriptively only. Most ± though not all ± of our patients were 
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treated with modern, inverse-planned radiotherapy. It is possible that more modern techniques 
have resulted in improved tumour targeting and/or better organ-at-risk sparing compared to 
older techniques, but this current dataset does not have sufficient numbers of patients treated 
with older techniques to allow such an analysis. None of the patients in this series received 
proton therapy, which may add additional benefits. Radiotherapy techniques, in particular the 
impact of protons, should therefore be the focus of further study. Finally, our data are not able 
to determine whether 23.4 Gy or 36 Gy CSI are optimal for locally recurrent ependymoma. 
 
There is published evidence supporting use of proton beam therapy to deliver CSI as 
definitive treatment for primary brain tumours in adults26 and children27. Proton CSI is 
associated with reduced acute toxicities26,27 as well as an expectation of reduced late toxicities 
due to dosimetric sparing of normal tissues in the torso.28-32 Given the high rates of disease 
control with CSI for locally recurrent ependymoma, proton CSI could be considered in this 
setting. There is an ongoing prospective study (ClinicalTrials.gov identifier, NCT02125786) 
that allows use of proton CSI for recurrent ependymoma. 
 
Conclusion 
In a molecularly-characterized cohort of paediatric patients, a statistically significant FFP 
benefit was observed among individuals with locally recurrent ependymoma treated with CSI 
as a component of re-irradiation, as compared with those treated with focal RT2 alone. This 
FFP benefit was also observed in the subgroup of patients with locally recurrent infratentorial 
tumours. Long-term follow-up is needed to see if CSI-RT2 results in an OS benefit with time. 
Our findings warrant further prospective investigation and validation in a larger multi-
institutional collaborative setting. Until these data become available, patients with locally 
recurrent ependymoma should be offered the option of repeat surgery and CSI as part of re-
irradiation to maximize the likelihood of disease control, though the potential benefits should 
be weighed against the long-term side effects of CSI. 
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Figure Legends 
Figure 1. a) Freedom-from-progression and b) overall survival from RT2  
 
Figure 2. Outcomes for re-irradiated patients with local failure, by RT2 field and site of 
disease. a) freedom-from-progression in all patients, b) overall survival in all patients; 
ca) freedom-from-progression in patients with infratentorial (IT) primaries, db) overall 
survival in patients with infratentorial IT primaries 
ec) freedom-from-progression in patients with supratentorial (ST) primaries, df) overall 
survival in patients with supratentorial ST primaries 
ae) freedom-from-progression in all patients, bf) overall survival in all patients; 
 
 
 
N-O-D-18-00629R1 
1 
 
Craniospinal irradiation as part of re-irradiation for children with recurrent 
intracranial ependymoma 
 
Running title 
CSI for recurrent ependymoma 
 
Authors 
Derek S. Tsang* MD MSc (1, 3) 
Louise Murray* PhD (1, 2) 
Vijay Ramaswamy MD PhD (3) 
Michal Zapotocky MD PhD (3, 4) 
Uri Tabori MD (3) 
Ute Bartels MD (3) 
Annie Huang MD PhD (3) 
Peter B. Dirks MD PhD (5) 
Michael D. Taylor MD PhD (5) 
Cynthia Hawkins MD PhD (6) 
Eric Bouffet MD (3) 
Normand Laperriere MD (1, 3) 
 
(1) Radiation Medicine Program, Princess Margaret Cancer Centre, University Health 
Network, Toronto, Canada 
(2) Radiotherapy Research Group, University of Leeds, Leeds, United Kingdom 
(3) Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada 
(4) Department of Paediatric Haematology and Oncology, 2nd Medical School, Charles 
University and University Hospital Motol, Prague, Czech Republic 
(5) Division of Neurosurgery, Hospital for Sick Children, Toronto, Canada 
0DQXVFULSW5HYLVHG
N-O-D-18-00629R1 
2 
 
(6) Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada 
* DST and LM contributed equally to this work. 
 
Corresponding author 
Derek S. Tsang 
610 University Avenue 
Toronto ON  M5G 2M9 
Canada 
416-946-2121 (tel) 
416-946-2111 (fax) 
derek.tsang@rmp.uhn.ca 
 
Conflicts of interest 
None 
 
Authorship 
Collected data: DST, LM, VR, MZ, MDT, CH, EB, NL 
Data analysis: DST, LM, EB 
Interpreted the data: All authors 
Wrote the manuscript: All authors 
 
Word count (abstract, text, references, figure legends): 5 641 
  
N-O-D-18-00629R1 
3 
 
Abstract 
Background: The goal of this study was to evaluate outcomes in children with relapsed, 
molecularly-characterized intracranial ependymoma treated with or without craniospinal 
irradiation (CSI) as part of a course of repeat radiation therapy (re-RT). 
 
Methods: This was a retrospective cohort study of 31 children. Patients with distant relapse 
received CSI as part of re-RT. For patients with locally recurrent ependymoma, those treated 
before 2012 were re-irradiated with focal re-RT. In 2012, institutional practice changed to 
offer CSI, followed by boost re-RT to the site of resected or gross disease.  
 
Results: Median follow-up was 5.5 years. Of 9 patients with distant relapse after initial RT, 2-
year freedom-from-progression (FFP) and overall survival (OS) were 12.5% and 62.5%, 
respectively. There were 22 patients with local failure after initial RT. In these patients, use of 
CSI during re-RT was associated with improvement in 5-year FFP (83.3% with CSI vs. 
15.2% with focal re-RT only, p = 0.030). In the subgroup of patients with infratentorial 
primary disease, CSI during re-RT also improved 5-year FFP (100% with CSI, 10.0% with 
focal re-RT only, p = 0.036). 23 patients had known molecular status; all had posterior fossa 
group A tumours (n = 17) or RELA-fused tumours (n = 6). No patient developed radiation 
necrosis after fractionated re-RT, though almost all survivors required assistance throughout 
formal schooling. Five out of ten long-term survivors have not developed neuroendocrine 
deficits. 
 
Conclusions: Re-irradiation with CSI is a safe and effective treatment for children with 
locally recurrent ependymoma and improves disease control as compared with focal re-
irradiation, with the benefit most apparent for those with infratentorial primary tumours.  
 
Keywords (MeSH) 
ependymoma, re-irradiation, recurrence, pediatrics 
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Key points 
- Re-RT for recurrent ependymoma is safe & provides disease control in some patients 
- CSI re-RT improves disease control in locally recurrent ependymoma 
- No case of necrosis solely attributable to fractionated re-RT was observed 
 
Importance of the Study 
This study reports clinical and toxicity outcomes of a cohort of children treated with repeat 
irradiation for recurrent ependymoma. In 2012, our institution changed practice to offer 
craniospinal irradiation (CSI) for patients with locally recurrent ependymoma, with focal re-
irradiation being routine prior to this date. This provided an ideal before-and-after cohort to 
evaluate the role of CSI. We found that CSI for locally recurrent ependymoma offered a 
freedom-from-progression benefit, especially for those with infratentorial tumours. No cases 
of radiation necrosis (in the absence of disease progression) were seen after fractionated re-
irradiation, though patients treated with re-RT are at risk of long-term cognitive & endocrine 
deficits. Given the improved disease control seen with comprehensive neuraxis re-irradiation, 
CSI should be discussed as an option for patients with locally recurrent ependymoma. 
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Introduction 
Ependymoma accounts for 9% of paediatric central nervous system (CNS) tumours, with 
90% arising intra-cranially1,2. At diagnosis, patients with localised disease typically undergo a 
maximal safe resection, followed by adjuvant post-operative radiotherapy (RT1) to the 
tumour bed.3,4 Challenges arise in the setting of recurrent disease, which occurs in 
approximately 30-50% of patients.4 Maximum safe resection is appropriate, and, in the 
absence of effective systemic therapy3,5,6, a second course of radiation (RT2) may be 
undertaken which overlaps with the first.7-9 Despite traditional concerns surrounding the 
potential side effects of re-irradiating the paediatric brain to cumulative doses above what 
would usually be considered normal tissue tolerance, this has been found to be well-tolerated, 
with low rates of radiation necrosis.8,9 
 
It has previously been demonstrated that re-irradiation for children with recurrent 
ependymoma results in improved survival compared to historical controls who were not 
treated with RT2.8 In the setting of disseminated relapse, patients should receive craniospinal 
irradiation (CSI) as a component of RT2, with subsequent boost RT to sites of gross or 
resected disease. However, the optimal radiation field for localized recurrence is controversial 
and not well-defined. For localised relapse without distant dissemination, patients have been 
typically re-irradiated with focal RT2 to the recurrent tumour bed.7-9 
 
Since our institution adopted focal re-irradiation for locally recurrent ependymoma, it has 
been observed that a large proportion of patients who relapse following focal RT2 
subsequently develop distant disease elsewhere within the neuraxis. This raised the question 
as to whether CSI as part of RT2 could improve disease control as compared with focal RT2. 
Since 2012 and onward, CSI has been offered as a standard treatment in the setting of locally 
recurrent ependymoma. This change created an ideal before-and-after cohort to study the role 
of CSI for recurrent intracranial ependymoma in children. Thus, the objectives of this study 
were to evaluate freedom-from-progression (FFP) and overall survival (OS) between patients 
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who were treated with or without CSI as a component of RT2, in a molecularly-characterized 
study cohort. 
 
Materials and Methods 
Paediatric patients age 18 or under (at the time of initial ependymoma diagnosis) who were 
treated at the Hospital for Sick Children and Princess Margaret Cancer Centre in Toronto, 
Canada between 1999 and 2018 were retrospectively reviewed. Eligible patients had a 
pathological diagnosis of intracranial ependymoma and received focal RT1 for localised 
disease at initial diagnosis. Those who subsequently relapsed and received at least one course 
of re-irradiation were identified from neuro-oncology and radiotherapy databases. Patients 
underwent repeat surgery at recurrence, when possible. 
 
Patients with recurrence at solely the site of the original disease, within the RT1 field, were 
considered to have local relapse. Patients with relapse distant to the site of original disease 
and/or malignant cells within the CSF were considered to have disseminated disease. Those 
with synchronous local aQGGLVWDQWIDLOXUHZHUHLQFOXGHGLQWKH³GLVVHPLQDWHG´JURXSGXHWR
the small number of combined failures (n = 3). For the infratentorial tumours, molecular 
subgroup characterization was performed on initial resection specimens using a combination 
of genome wide methylation arrays 10 and H3K27me3 immunohistochemistry staining.11,12  
Two cases had tissue that could not be characterized due to weak H3K27me3 staining and 
lack of further tissue for methylation profiling. In the supratentorial tumours, a genome-wide 
methylation array was used to characterize RELA fusions.13 
 
Radiotherapy 
At the time of initial presentation (RT1), FKLOGUHQPRQWKVRUPRQWKV received 54 Gy 
or 59.4 Gy in 1.8 Gy daily fractions to the post-operative tumour bed, respectively. For 
patients who relapsed with localised disease, our institutional practice had been to offer focal 
re-irradiation (RT2) until 2011. Focal RT2 dose was adapted to RT1 dose; those who had 
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received RT1 59.4 Gy were treated with RT2 54 Gy, while those who had received RT1 54 
Gy were treated with RT2 59.4 Gy (Figure e1). The GTV included the recurrent, post-
operative tumour bed and all macroscopic disease with 0-1 cm CTV margin and 0-0.5 cm 
PTV margin, depending on proximity to organs at risk. Where the RT2 prescription dose was 
59.4 Gy and the PTV overlapped with brainstem, cord or optic structures, a two-phase plan 
was adopted: the PTV was treated to 54 Gy, followed by a boost treatment (5.4 Gy in 3 
fractions) with reduced margins to minimize overlap with critical structures. Two patients 
received cobalt-based stereotactic radiosurgery (SRS; 15-24 Gy) using a rigid stereotactic 
frame (Elekta AB, Sweden) for small, isolated local recurrences. 
 
From 2012 and onward, CSI as a component of RT2 (CSI-RT2) was adopted as a standard 
option for patients with isolated focal relapse (Figure e1). 23.4-36 Gy were delivered to the 
whole neuraxis in 1.8 Gy daily fractions, with lower doses reserved for selected younger 
patients (age 8 or under, see Table e1). Focal boosts of 54-59.4 Gy were delivered to the 
recurrent post-operative tumour bed and any residual macroscopic disease as described above. 
Similarly, patients who relapsed with disseminated disease received 36 Gy CSI, followed by 
boost RT2 to 54-59.4 Gy.  
 
All patients were treated with photon external beam RT. The shortest RT1-to-RT2 time 
interval in the study was 6 months, with all remaining patients having at least a 10-month gap 
between the two treatments to allow for potential normal tissue recovery. At re-irradiation, 
brainstem, cord and optic doses were limited to a point maximum of 54 Gy, aiming for 95% 
PTV coverage with 95% of the RT2 prescription dose; no cumulative dose limits were 
applied. No doses >100% of the prescription dose were permitted in brainstem, optics or cord 
for RT2. CSI included all structures in the brain and spinal cord, without shielding applied to 
optic structures, brainstem, or cervical spinal cord. All re-irradiated patients received real-
time image guidance with daily cone beam computed tomography. Post-treatment 
surveillance MR imaging was used to detect tumor recurrences or radiation necrosis. When 
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available, MR spectroscopy was used to help differentiate between necrosis or recurrence. In 
cases of diagnostic uncertainty, short-interval repeat imaging was used to clarify the true 
diagnosis. 
 
Analysis 
Clinical characteristics were reported descriptively; proportions and continuous variables 
ZHUHFRPSDUHGXVLQJ)LVKHU¶VH[DFWWHVW and the Wilcoxon rank-sum test, respectively. The 
Kaplan-Meier method was used to calculate OS and FFP (defined as time to disease 
recurrence) from the first day of RT2. Living patients were censored at last follow-up. 
Median follow-up was calculated by reversing the censoring variable in the Kaplan-Meier 
analysis for death. OS and FFP, stratified by clinicopathologic factors, were compared using 
log-rank tests. Cox regression was used to explore univariate factors associated with OS and 
FFP, and to evaluate statistical interaction between variables. Multivariable analysis was not 
performed due to the small sample size. Analyses were performed using SAS version 9.4 
(Cary, NC, USA). The study was approved by the research ethics boards of both the 
University Health Network and Hospital for Sick Children. 
 
Results 
We identified 31 patients who were re-irradiated for relapsed ependymoma. Baseline 
characteristics are summarised in Table 1, and individual patient data are listed in Table e2. 
All patients underwent surgery at initial presentation prior to RT1. For all but one patient, 
RT1 was delivered at initial presentation, and the remaining patient received surgery and 
chemotherapy initially, and RT1 at first recurrence. In total, 10 patients received 
chemotherapy at initial presentation, either to delay radiotherapy due to young age (n = 2), to 
facilitate more complete surgery (n = 5, 1 patient eventually proceeded to second surgery), as 
adjuvant therapy (n = 2), and as an alternative to radiotherapy (in the 1 patient who received 
RT1 at first relapse, chemotherapy was given at first presentation to facilitate further surgery). 
23 patients (74%) had complete molecular subgroup characterization; all the patients with 
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infratentorial tumours had group A tumours while all the supratentorial tumours had RELA 
fusions. There were no patients with posterior fossa group B tumours. 
 
Surgery was recommended to reduce the burden of disease as well as to obtain pathologic 
confirmation of recurrence prior to embarking on RT2. A majority of patients underwent 
surgery for relapsed ependymoma, with 65% achieving GTR. Of 16 patients without GTR at 
first surgery and subsequent local recurrence, 10 achieved GTR at subsequent surgery for 
recurrence because: a) first surgery was done by a different surgeon at an outside institution 
(n = 5); b) more aggressive surgery near critical structures was performed at recurrence (n = 
4); c) revised pathologic diagnosis from glioma to ependymoma after first surgery (n = 1). 
Nine patients relapsed with macroscopic disseminated disease, including three with 
concurrent local relapse. Of these nine, six underwent tumour resection; three had more 
extensive recurrences; of these three, one underwent biopsy, and two had no surgery. 
 
Of all patients, 22 relapsed locally, without radiologic or pathologic evidence of 
dissemination. Among these children, 15 underwent focal RT2 (13 with fractionated RT2, 
and 2 using single fraction SRS). The 2 patients who received SRS for small recurrences in 
the original tumour bed did not have surgery prior to RT2. 7 patients with local relapse 
received CSI-RT2, with a further boost to the local site of recurrence. One patient amongst 
these seven (patient 14) had suspicious cerebrospinal fluid cytology prior to RT2 without 
macroscopic evidence of distant disease. There was no statistically significant difference in 
the proportion of locally recurrent patients who attained a GTR versus not before RT2, 
between the focal or CSI RT2 groups (p = 0.35). The median age at RT2 was 6.4 years 
(range, 5.3-8.4) and 13.2 years (range, 7.3-22.3) amongst those who received 23.4 Gy (n = 4) 
and 36 Gy (n = 3) CSI for locally recurrent disease, respectively (p = 0.057). The shortest 
RT1-to-RT2 time interval in the study was 6 months, with a median interval of 23 months.  
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Of all re-irradiated patients, 27 received re-irradiation at the time of first recurrence and 3 
received re-irradiation at second recurrence (with surgery and/or chemotherapy at first 
recurrence). One patient received RT at third recurrence. The mean and median combined 
RT1 and RT2 physical prescriptions were 106 Gy and 113 Gy, respectively. 
 
Survival 
Median follow-up was 65.3 months. Median FFP was 23.3 months (95% CI 13.6-43.5), with 
a 3- and 5-year FFP of 38.6% (95% CI 20.6-56.4) and 24.1% (95% CI 9.4-42.5; Figure 1). 
Because no patient died without the presence of progressive ependymoma, FFP was equal to 
progression-free survival. The median survival for the entire cohort was 53.1 months (95% CI 
28.4-94.5), with a 3- and 5-year OS of 62.8% (95% CI 41.7-78.0) and 39.9% (95% CI 20.5-
58.7). 
 
Amongst those with local failures after RT1, use of CSI-RT2 was associated with a 
statistically significant improvement in FFP. The median FFP was 26.7 months (95% CI 9.1-
43.5) in those who did not receive CSI-RT2, versus not reached for those who received CSI-
RT2 (log-rank p = 0.030, Figure 2). The 5-year FFP was 15.2% (95% CI 2.5-38.2) versus 
83.3% (95% CI 27.3-97.5) for no CSI versus CSI-RT2, respectively. However, this difference 
did not translate into a statistically significant difference in OS, with a 5-year OS of 43.1% 
(95% CI 17.9-66.2) versus 80.0% (95% CI 20.4-96.9; log-rank p = 0.23) for no CSI versus 
CSI-RT2, respectively. 
 
Among 22 patients with infratentorial (IT) ependymoma, 16 experienced local failures after 
RT1. Of those, four received CSI as part of RT2 while 12 received focal RT2. In an 
exploratory subgroup analysis of patients with IT ependymoma and local relapse, CSI-RT2 
was associated with improvement in 5-year FFP (100% [95% CI 100-100]) as compared to 
those treated with focal RT2 only (10.0% [95% CI 0.6-35.5], log-rank p = 0.036, Figure 2). 
There may be an associated OS improvement (5-year survival of 100% [95% CI 100-100] vs. 
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36.7% [95% CI 11.3-63.0], respectively) but this did not reach statistical significance (log-
rank = 0.093). 
 
Among 9 patients with supratentorial (ST) ependymoma, 6 experienced local failures after 
RT1; of these, half received CSI as part of RT2. In an exploratory subgroup analysis of 
patients with ST ependymoma and local relapse, CSI-RT2 was not associated with 
differences in FFP or OS, likely due to a small sample size (Figure 2).  
 
Because the radiation treatment technique differed between fractionated RT2 and SRS RT2, 
analyses were repeated after excluding all children treated with a second course of radiation 
using SRS (n = 2). Results are shown in Figure e2. Use of CSI-RT2 continued to be 
associated with a statistically significant FFP benefit amongst the entire cohort (log-rank p = 
0.016) and in the subgroup of patients with infratentorial primary tumors (log-rank p = 
0.039). 
 
Amongst all patients with distant failures after RT1, CSI was always given. Despite this 
treatment, there were no long-term survivors beyond 5 years. Median survival was 30.3 
months; 2-year and 4-year OS probabilities were 62.5% (95% CI 22.9-86.1) and 37.5% (95% 
CI 8.7-67.4), respectively. Median FFP was 16.6 months, with a 2-year FFP probability of 
12.5% (95% CI 0.6-42.3). 
 
Factors associated with OS and FFP are listed in Table 2. On univariate analysis, no factor 
was significantly associated with OS. There was strong trend to improved FFP with use of 
CSI for local failures after RT1. There was no interaction between use of CSI and the extent 
of surgery before RT1 (p = 0.81) or before RT2 (p = 0.64) for the FFP endpoint. Sex was 
excluded from this analysis because all patients with locally recurrent ependymoma treated 
after 2011 with CSI-RT2 were males. Few females, who have a better prognosis overall 4,14, 
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recurred after 2011; thus far, none had yet been treated with CSI for a locally recurrent 
ependymoma. 
 
The patterns of failure after RT2, stratified by type of RT1 failure and treatment received, are 
listed in Table 3. Most patients who received CSI-RT2 for local failure after RT1 did not 
recur; one patient in this group developed recurrent disease outside the RT2 boost volume 
(but within the CSI-RT2 treated volume).  
 
Toxicities and functional outcomes after RT2 
Patients who were treated with RT2 tolerated re-treatment well, with no high-grade acute 
toxicities. All patients completed the planned course of RT2 re-irradiation. 
 
One patient developed radiation necrosis attributable to RT2; patient 7 developed grade 3 
necrosis after SRS RT2 that was treated with dexamethasone alone. The patient had some 
neurologic recovery but remained ataxic and wheelchair-dependent; this individual eventually 
developed local disease progression and died. Two patients developed tumour progression 
with evidence of necrosis after RT2 (patients 3 and 24). Three other patients developed 
necrosis: one after RT3 (21 Gy SRS; patient 1), one after fractionated RT3 (36 Gy CSI 
followed by in-field supratentorial boost to 54 Gy with RT1 and RT2 overlap; patient 6), and 
one after a fifth course of RT (SRS, patient 12). Treatments for necrosis included observation 
(patient 3 and 12), dexamethasone only (patients 1 and 7), bevacizumab (patients 6 and 24), 
and hyperbaric oxygen (patient 6). 
 
Functional outcomes among ten long-term survivors without evidence of active disease 
(median follow-up: 59.8 months) are listed in Table 4. Most individuals had mild or moderate 
difficulties with formalized education, requiring additional assistance in the form of an 
individualized education plan.15 Two patients ± including one who received CSI ± were able 
to enroll in a post-secondary education programme. Half of all surviving patients did not, or 
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have not yet, developed neuroendocrine deficits; of the five who developed such deficits, 3 
received 23.4 Gy CSI and 2 received 36 Gy. 
 
Third course of radiation 
Following RT2, eight patients went on to receive at least one more course of radiotherapy, 
with overlap with RT1 or RT2 in seven individuals. Three patients received whole spine RT3 
followed by focal spine boosts, two received fractionated focal RT3, two received CSI 
followed by boost RT, and one received SRS. Of all eight patients, two had received prior 
CSI as part of RT2 (36 Gy, patients 18 and 21). Individual cases are discussed in detail in the 
Supplementary Material. Median survival after a third course of radiotherapy (RT3) was 19.3 
months, and median FFP was 8.8 months. In patient 2, RT3 led to long-term survival (>5 
years from RT3); this individual was treated with focal RT2 but suffered distant failure; RT3 
consisting of 23.4 Gy CSI and boost to all sites of disease led to long-term disease control.  
 
Discussion 
We present 31 paediatric patients treated with a repeat course of radiation for relapsed 
intracranial ependymoma. Most patients had NTR or GTR prior to RT2. Our institutional 
practice to systematically offer CSI to patients with recurrent local disease from 2012 
onwards created an ideal quasi-experimental before-and-after cohort to study the role of CSI 
in treatment of locally recurrent intracranial ependymoma. This study found that CSI was 
associated with a statistically significant improvement in FFP, particularly in the setting of 
local recurrence of infratentorial (posterior fossa) ependymoma. There was also a trend to 
improved OS with use of CSI-RT2 for locally recurrent infratentorial ependymoma. 
 
A majority of patients (n = 23) had successful molecular subgroup characterization. This is 
the first known study of recurrent intracranial ependymoma to include molecular and 
methylation subgroup information. It is well-known that posterior fossa group A and RELA-
fused tumours carry a worse prognosis 13,16; thus, it is not surprising that our cohort comprised 
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exclusively of these tumours. Gain of chromosome 1q is also known as a negative prognostic 
factor 17,18; in a large cohort of patients treated at St. Jude &KLOGUHQ¶V5HVHDUFK+RVSLWDO, 
patients with recurrent intracranial ependymoma treated with repeat RT were enriched for 
both 1q gain and RELA fusions.9 
 
Prior studies 
Merchant et al. from St. Jude were the first to report detailed outcomes for paediatric patients 
re-irradiated for ependymoma7 with a recent update by Tsang et al.9 There were 46 locally 
recurrent patients who received focal RT2 and 10 patients who received CSI as part of RT2. 
In a multivariable analysis, use of CSI for locally recurrent disease was not associated with a 
statistically significant improvement in OS or FFP. CSI did eliminate disseminated failures 
after RT2, whereas 44% of recurrences after focal RT2 were distant-only failures. Patients 
selected for RT2-CSI with locally recurrent ependymoma in this study likely had attributes of 
more aggressive disease. 
 
A survey of the management of 108 children with relapsed ependymoma was reported by 
Messahel et al.19. 69% of these children had local-only relapse. In a comparison of all 
patients, including those with distant recurrence, children who received CSI at relapse (n = 
10) had improved survival compared to those irradiated focally at relapse (n = 17) and those 
who did not receive radiotherapy at relapse (n = 45). Only 14 of these 27 irradiated patients 
had RT as re-irradiation; nonetheless, as with this current study, CSI as a component of 
salvage therapy was associated with improved outcomes. 
 
Few other studies have reported specifically upon the use of CSI for locally recurrent 
ependymoma. In a series by Lobon et al., 15 patients with local recurrences were treated with 
focal irradiation, with a crude disease control rate of 40%.20 Distant failures represented about 
half of post-RT2 recurrences. In a study by Eaton et al., 11 patients with locally recurrent 
ependymoma were re-treated with focal proton therapy.21 In this subgroup, five experienced 
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further local failures after RT2 without any cases of distant failures. Outcomes for up to 12 
re-irradiated patients are included within other series.22-24 For example, in the study by Combs 
et al., 3-year progression-free and overall survival for seven patients focally re-irradiated for 
local recurrence were 64% and 83%, respectively, following a median dose of 36 Gy (range 
20-60 Gy) in 1.8-2.0 Gy fractions.23 Survival outcomes were comparable to those observed in 
this current study for focally re-irradiated patients. 
 
Radiation necrosis 
Some caution may be required if using a hypofractionated schedule for re-irradiation in young 
patients: Hoffman et al. described hypofractionated RT2 in 11 paediatric patients with locally 
recurrent ependymoma using 24 Gy in 3 fractions with excellent local control (3-year LC 
89%).25 However, radiation necrosis occurred in 45% of re-irradiated patients (n = 5), two of 
whom required treatment with bevacizumab.25 Merchant et al. reported low rates of disease 
control and high rates of necrosis (crude rate 83%) in 6 patients re-irradiated with SRS.7 In 
the present study, there were two individuals who developed evidence of tumour progression 
synchronously with necrosis after RT2. The remaining four instances of necrosis occurred 
after SRS or irradiation after RT2. Therefore, our contemporary practice is to deliver RT2 
using daily fractions of 1.8 Gy per day. 
 
To our knowledge, this is one of three largest series examining re-irradiation in children with 
relapsed ependymoma. It is also the only known study to specifically evaluate CSI as part of 
RT2 in the setting of isolated focal relapse, and to report the molecular subgrouping of 
recurrent pediatric ependymoma. However, there are some important differences between 
these data and the cases previously reported in the literature. 
 
First, in the present study, those with disseminated relapse after RT1 had poor outcomes, with 
no long-term survivors, despite treatment with CSI as part of RT2. This is in contrast to the 
data from St. Jude9 and from France20 which showed that those with distant failures treated 
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with CSI did well. In the present study, the interval between RT1-to-failure was 1.4 years 
among those with disseminated relapse, comparable to the French data (1.2 years for all 
patients) and the St. Jude cohort (1.8 years for all patients). In our dataset, those with 
combined local and distant failure, a recognized poor prognostic factor9,  were categorized 
together iQRQH³GLVVHPLQDWHG´JURXSGXHWRWKHVPDOOQXPEHUVRISDWLHQWVZLWKFRPELQHG
failures; this may have negatively affected the overall outcome of this cohort. Second, all but 
one of these patients had anaplastic histology at diagnosis, which may be challenging to 
control, even with RT2.9 There can also be a referral bias among studies in the literature, 
whereby patients with a better prognostic profile may be included, resulting in improved 
outcomes reported by other research groups as compared to our present study which included 
an unselected group of patients. Overall, longer-term follow-up is needed to better elucidate 
the true nature of this high-risk subgroup of children. 
 
This study has some limitations. Although associated with a large FFP benefit, the number of 
patients with local recurrence after RT1 treated with CSI-RT2 was small (n = 7). Detailed 
tests of neuropsychological function after RT2 were only available for four patients and are 
not reported here due to small numbers. Furthermore, infratentorial and supratentorial 
ependymoma are two different disease entities with different molecular alterations; as such, 
they should be considered separately.17 To date, re-irradiation studies have not handled 
ependymoma in this manner. Although our subgroup analysis of infratentorial tumours 
demonstrated a FFP benefit to CSI-RT2, greater patient numbers are needed to validate these 
findings. There were insufficient patient numbers to rigorously evaluate the role of CSI-RT2 
in supratentorial tumours, neither in those with local or disseminated recurrence; these are 
subgroups deserving of further study. There were also insufficient events to perform a 
multivariable analysis. Testing for 1q chromosome gain was not performed. It was not 
possible to stratify results by molecular subgroup because all the supratentorial tumours had 
RELA fusions and no infratentorial patient had PF-B pathology; therefore, molecular 
pathology was reported descriptively only. Most ± though not all ± of our patients were 
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treated with modern, inverse-planned radiotherapy. It is possible that more modern techniques 
have resulted in improved tumour targeting and/or better organ-at-risk sparing compared to 
older techniques, but this current dataset does not have sufficient numbers of patients treated 
with older techniques to allow such an analysis. None of the patients in this series received 
proton therapy, which may add additional benefits. Radiotherapy techniques, in particular the 
impact of protons, should therefore be the focus of further study. Finally, our data are not able 
to determine whether 23.4 Gy or 36 Gy CSI are optimal for locally recurrent ependymoma. 
 
There is published evidence supporting use of proton beam therapy to deliver CSI as 
definitive treatment for primary brain tumours in adults26 and children27. Proton CSI is 
associated with reduced acute toxicities26,27 as well as an expectation of reduced late toxicities 
due to dosimetric sparing of normal tissues in the torso.28-32 Given the high rates of disease 
control with CSI for locally recurrent ependymoma, proton CSI could be considered in this 
setting. There is an ongoing prospective study (ClinicalTrials.gov identifier, NCT02125786) 
that allows use of proton CSI for recurrent ependymoma. 
 
Conclusion 
In a molecularly-characterized cohort of paediatric patients, a statistically significant FFP 
benefit was observed among individuals with locally recurrent ependymoma treated with CSI 
as a component of re-irradiation, as compared with those treated with focal RT2 alone. This 
FFP benefit was also observed in the subgroup of patients with locally recurrent infratentorial 
tumours. Long-term follow-up is needed to see if CSI-RT2 results in an OS benefit with time. 
Our findings warrant further prospective investigation and validation in a larger multi-
institutional collaborative setting. Until these data become available, patients with locally 
recurrent ependymoma should be offered the option of repeat surgery and CSI as part of re-
irradiation to maximize the likelihood of disease control, though the potential benefits should 
be weighed against the long-term side effects of CSI. 
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Figure Legends 
Figure 1. a) Freedom-from-progression and b) overall survival from RT2  
 
Figure 2. Outcomes for re-irradiated patients with local failure, by RT2 field and site of 
disease. a) freedom-from-progression in patients with infratentorial (IT) primaries, b) overall 
survival in patients with IT primaries 
c) freedom-from-progression in patients with supratentorial (ST) primaries, d) overall 
survival in patients with ST primaries 
e) freedom-from-progression in all patients, f) overall survival in all patients 
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Table 1. Baseline characteristics 
Characteristic Local failure Distant failure All (n = 31) 
Focal RT2 
(n = 15) 
CSI RT2 
(n = 7) 
CSI RT2 
(n = 9) 
N (%) 
Sex (Female) 7 (47) 0 (0) 4 (44.4) 11 (35.5) 
     
Age at diagnosis, 
years (median, range) 
4.8 (0.8-12.9) 4.9 (1.7-12.6) 8.3 (4.7-17.2) 6.1 (0.8-
17.2) 
Site of original 
disease 
     Infratentorial 
PF-A 
Not known 
     Supratentorial 
RELA fusion 
Not known 
 
 
12 (20.0) 
7 (100) 
5 
3 (80.0) 
1 (100) 
2 
 
 
4 (57.1) 
4 (100) 
 
3 (42.9) 
2 (100) 
1 
 
 
6 (66.7) 
6 (100) 
 
3 (33.3) 
3 (100) 
 
 
22 (80.0) 
17 (100) 
5 
9 (29.0) 
6 (100) 
3 
Histological grade 
     II 
     III 
 
7 (46.7) 
8 (53.3) 
 
4 (57.1) 
3 (42.9) 
 
1 (11.1) 
8 (88.9) 
 
12 (38.7) 
19 (61.3) 
Initial surgery 
     GTR 
     NTR 
     STR 
 
3 (20) 
78 (53.346.7) 
54 (26.733.3) 
 
3 (42.9) 
1 (14.3) 
3 (42.9) 
 
6 (66.7) 
2 (22.2) 
1 (11.1) 
 
12 (38.7) 
101 
(32.35.5) 
98 (29.05.8) 
Age at RT1, years 5.0 (1.2-13.0) 5.1 (1.8-12.7) 8.3 (4.8-17.5) 6.2 (1.2-
17.5) 
7DEOHVVKRZFKDQJHV
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Chemotherapy at 
initial presentation 
     Yes* 
     No 
 
 
6 (40) 
9 (60) 
 
 
3 (42.9) 
4 (57.1) 
 
 
1 (11.1) 
8 (88.9) 
 
 
10 (32.3) 
21 (67.7) 
Time to first relapse, 
months (median, 
range) 
23.6 (8.5-105.5) 29.4 (3.7-
138.3) 
14.8 (8.6-97.3) 19.4 (3.7-
138.3) 
Surgery at relapse 
     GTR 
     NTR 
     STR 
     Biopsy only 
     None 
 
9 (60) 
1 (6.7) 
3 (20) 
 
2 (13.3) 
 
6 (85.7) 
 
1 (14.3) 
 
5 (55.6) 
1 (11.1) 
 
1 (11.1) 
2 (22.2) 
 
20 (64.5) 
2 (6.5) 
4 (12.9) 
1 (3.2) 
4 (12.9) 
Time between RT1 
and RT2, years 
(median, range) 
2.4 (0.9-10.0) 2.6 (0.5-11.7) 1.4 (0.9-8.2) 1.9 (0.549-
11.7) 
Age at RT2, years 
(median, range) 
7.1 (2.4-16.9) 8.4 (5.3-22.3) 10.2 (6.5-18.4) 8.4 (2.4-
22.3) 
CSI RT2 treatment 
technique 
     2D 
     IMRT 
     Not known** 
  
 
6 (85.7) 
1 (14.3) 
 
 
7 (87.5) 
1 (12.5) 
1 
 
Focal or boost RT2 
treatment technique 
     3DCRT 
     IMRT or VMAT 
 
 
 
13 (86.7) 
 
 
 
7 (100) 
 
 
2 (25.0) 
6 (75.0) 
 
 
2 (6.7) 
26 (86.7) 
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     SRS 
     Not known** 
2 (13.3)  
1 
2 (6.7) 
1 
*Chemotherapy consisted of i) vincristine, carboplatin, cyclophosphamide and etoposide, or ii) 
carboplatin, procarbazine, etoposide, cisplatin, vincristine and cyclophosphamide, or iii) 
cyclophosphamide, vincristine, cisplatin and etoposide, or iv) temozolopmide 
**One individual received RT2 at an outside institution. 
 
2D = two-dimensional; 3DCRT = three-dimensional conformal radiation therapy; IMRT = intensity 
modulated radiation therapy; GTR = gross total resection; NTR = near total resection; PF-A = 
posterior fossa group A tumour; STR = subtotal resection;  VMAT = volumetric arc radiation therapy
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Table 2. Clinicopathologic factors associated with overall survival (OS) and freedom-from 
progression (FFP) after RT2 on univariate analysis 
Variable Overall survival Freedom from progression 
 HR (95% CI) p HR (95% CI) p 
Supratentorial (vs. 
infratentorial) 
1.1 (0.41-3.0) 0.84 0.98 (0.37-2.5) 0.98 
Less than GTR before 
RT1 (vs. GTR) 
2.0 (0.65-6.2) 0.22 2.6 (0.92-7.1) 0.071 
Less than GTR before 
RT2 (vs. GTR) 
1.9 (0.74-5.0) 0.18 1.7 (0.69-4.0) 0.26 
Treatment group     
LF/focal RT2 Reference  Reference  
LF/CSI RT2 0.30 (0.04-2.4) 0.26 0.14 (0.02-1.1) 0.061 
dissem/CSI RT2 2.5 (0.82-7.4) 0.11 1.5 (0.57-4.1) 0.40 
Time between RT1 and 
RT2 (per year) 
0.93 (0.77-1.1) 0.52 0.91 (0.75-1.1) 0.35 
CSI = craniospinal irradiation; dissem = disseminated or combined (distant and local) failure 
after RT1; GTR = gross total resection; LF = local failure after RT1; RT1 = first course of 
radiotherapy; RT2 = second course of radiotherapy 
 
 
Table 3. Patterns of failure after RT2 
Pattern of failure after RT2 Local failure after RT1 Distant failure after RT1 
Focal RT2 
(n = 15) 
CSI RT2 
(n = 7) 
CSI RT2 
(n = 9) 
n (%) 
No recurrence 3 (20) 6 (86) 2 (20) 
N-O-D-18-00629R1 
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Local failure 6 (40)   
Disseminated failure 6 (40) 1 (14) 7 (70) 
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Table 4. Functional outcomes among survivors without active disease* 
Patient 
no. 
Age at 
RT2 
RT2 field Follow-up time 
since RT2 (months) 
School performance at last follow-up Neuroendocrine deficits 
2 5.4 
focal (RT3 
CSI 23.4 Gy) 81.4 
Attends regular school with extra help in mathematics and 
language 
Hypothyroidism and GH 
deficiency 
5 11.2 SRS 117.1 Attended post-secondary education (university) None 
9 22.3 CSI 36 Gy 65.3 Gainfully employed but with some neurocognitive deficits None 
11 3.3 focal 81.6 Developmental delay with delayed speech None 
13 5.3 CSI 23.4 Gy 54.3 Attends regular school with extra help with language GH deficiency 
14 9.8 CSI 36 Gy 95.6 
Attends post-secondary education (university) Hypothyroidism and GH 
deficiency 
16 13.2 CSI 36 Gy 35.9 
Attends regular school with extra help for mathematics and 
science 
Irregular menses 
26 6.6 focal 19.8 
Attends regular school with extra help for mathematics; has 
grade 2 ataxia 
None 
27 8.4 CSI 23.4 Gy 23.1 Attends regular school with extra help for language (2 grades None 
N-O-D-18-00629R1 
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behind) and mathematics (1 grade behind) 
28 6.1 CSI 23.4 Gy 22.6 Attends regular school GH deficiency 
*Two individuals with <18 months of follow-up are excluded from this table 
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Table 1. Baseline characteristics 
Characteristic Local failure Distant failure All (n = 31) 
Focal RT2 
(n = 15) 
CSI RT2 
(n = 7) 
CSI RT2 
(n = 9) 
N (%) 
Sex (Female) 7 (47) 0 (0) 4 (44.4) 11 (35.5) 
     
Age at diagnosis, 
years (median, range) 
4.8 (0.8-12.9) 4.9 (1.7-12.6) 8.3 (4.7-17.2) 6.1 (0.8-
17.2) 
Site of original 
disease 
     Infratentorial 
PF-A 
Not known 
     Supratentorial 
RELA fusion 
Not known 
 
 
12 (20.0) 
7 (100) 
5 
3 (80.0) 
1 (100) 
2 
 
 
4 (57.1) 
4 (100) 
 
3 (42.9) 
2 (100) 
1 
 
 
6 (66.7) 
6 (100) 
 
3 (33.3) 
3 (100) 
 
 
22 (80.0) 
17 (100) 
5 
9 (29.0) 
6 (100) 
3 
Histological grade 
     II 
     III 
 
7 (46.7) 
8 (53.3) 
 
4 (57.1) 
3 (42.9) 
 
1 (11.1) 
8 (88.9) 
 
12 (38.7) 
19 (61.3) 
Initial surgery 
     GTR 
     NTR 
     STR 
 
3 (20) 
7 (46.7) 
5 (33.3) 
 
3 (42.9) 
1 (14.3) 
3 (42.9) 
 
6 (66.7) 
2 (22.2) 
1 (11.1) 
 
12 (38.7) 
10 (32.3) 
9 (29.0) 
Age at RT1, years 5.0 (1.2-13.0) 5.1 (1.8-12.7) 8.3 (4.8-17.5) 6.2 (1.2-
17.5) 
Chemotherapy at     
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initial presentation 
     Yes* 
     No 
 
6 (40) 
9 (60) 
 
3 (42.9) 
4 (57.1) 
 
1 (11.1) 
8 (88.9) 
 
10 (32.3) 
21 (67.7) 
Time to first relapse, 
months (median, 
range) 
23.6 (8.5-105.5) 29.4 (3.7-
138.3) 
14.8 (8.6-97.3) 19.4 (3.7-
138.3) 
Surgery at relapse 
     GTR 
     NTR 
     STR 
     Biopsy only 
     None 
 
9 (60) 
1 (6.7) 
3 (20) 
 
2 (13.3) 
 
6 (85.7) 
 
1 (14.3) 
 
5 (55.6) 
1 (11.1) 
 
1 (11.1) 
2 (22.2) 
 
20 (64.5) 
2 (6.5) 
4 (12.9) 
1 (3.2) 
4 (12.9) 
Time between RT1 
and RT2, years 
(median, range) 
2.4 (0.9-10.0) 2.6 (0.5-11.7) 1.4 (0.9-8.2) 1.9 (0.5-
11.7) 
Age at RT2, years 
(median, range) 
7.1 (2.4-16.9) 8.4 (5.3-22.3) 10.2 (6.5-18.4) 8.4 (2.4-
22.3) 
CSI RT2 treatment 
technique 
     2D 
     IMRT 
     Not known** 
  
 
6 (85.7) 
1 (14.3) 
 
 
7 (87.5) 
1 (12.5) 
1 
 
Focal or boost RT2 
treatment technique 
     3DCRT 
     IMRT or VMAT 
     SRS 
 
 
 
13 (86.7) 
2 (13.3) 
 
 
 
7 (100) 
 
 
2 (25.0) 
6 (75.0) 
 
 
 
2 (6.7) 
26 (86.7) 
2 (6.7) 
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     Not known** 1 1 
*Chemotherapy consisted of i) vincristine, carboplatin, cyclophosphamide and etoposide, or ii) 
carboplatin, procarbazine, etoposide, cisplatin, vincristine and cyclophosphamide, or iii) 
cyclophosphamide, vincristine, cisplatin and etoposide, or iv) temozolomide 
**One individual received RT2 at an outside institution. 
 
2D = two-dimensional; 3DCRT = three-dimensional conformal radiation therapy; IMRT = intensity 
modulated radiation therapy; GTR = gross total resection; NTR = near total resection; PF-A = 
posterior fossa group A tumour; STR = subtotal resection;  VMAT = volumetric arc radiation therapy
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Table 2. Clinicopathologic factors associated with overall survival (OS) and freedom-from 
progression (FFP) after RT2 on univariate analysis 
Variable Overall survival Freedom from progression 
 HR (95% CI) p HR (95% CI) p 
Supratentorial (vs. 
infratentorial) 
1.1 (0.41-3.0) 0.84 0.98 (0.37-2.5) 0.98 
Less than GTR before 
RT1 (vs. GTR) 
2.0 (0.65-6.2) 0.22 2.6 (0.92-7.1) 0.071 
Less than GTR before 
RT2 (vs. GTR) 
1.9 (0.74-5.0) 0.18 1.7 (0.69-4.0) 0.26 
Treatment group     
LF/focal RT2 Reference  Reference  
LF/CSI RT2 0.30 (0.04-2.4) 0.26 0.14 (0.02-1.1) 0.061 
dissem/CSI RT2 2.5 (0.82-7.4) 0.11 1.5 (0.57-4.1) 0.40 
Time between RT1 and 
RT2 (per year) 
0.93 (0.77-1.1) 0.52 0.91 (0.75-1.1) 0.35 
CSI = craniospinal irradiation; dissem = disseminated or combined (distant and local) failure 
after RT1; GTR = gross total resection; LF = local failure after RT1; RT1 = first course of 
radiotherapy; RT2 = second course of radiotherapy 
 
 
Table 3. Patterns of failure after RT2 
Pattern of failure after RT2 Local failure after RT1 Distant failure after RT1 
Focal RT2 
(n = 15) 
CSI RT2 
(n = 7) 
CSI RT2 
(n = 9) 
n (%) 
No recurrence 3 (20) 6 (86) 2 (20) 
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Local failure 6 (40)   
Disseminated failure 6 (40) 1 (14) 7 (70) 
 
N-O-D-18-00629R1 
6 
 
Table 4. Functional outcomes among survivors without active disease* 
Patient 
no. 
Age at 
RT2 
RT2 field Follow-up time 
since RT2 (months) 
School performance at last follow-up Neuroendocrine deficits 
2 5.4 
focal (RT3 
CSI 23.4 Gy) 81.4 
Attends regular school with extra help in mathematics and 
language 
Hypothyroidism and GH 
deficiency 
5 11.2 SRS 117.1 Attended post-secondary education (university) None 
9 22.3 CSI 36 Gy 65.3 Gainfully employed but with some neurocognitive deficits None 
11 3.3 focal 81.6 Developmental delay with delayed speech None 
13 5.3 CSI 23.4 Gy 54.3 Attends regular school with extra help with language GH deficiency 
14 9.8 CSI 36 Gy 95.6 
Attends post-secondary education (university) Hypothyroidism and GH 
deficiency 
16 13.2 CSI 36 Gy 35.9 
Attends regular school with extra help for mathematics and 
science 
Irregular menses 
26 6.6 focal 19.8 
Attends regular school with extra help for mathematics; has 
grade 2 ataxia 
None 
27 8.4 CSI 23.4 Gy 23.1 Attends regular school with extra help for language (2 grades None 
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behind) and mathematics (1 grade behind) 
28 6.1 CSI 23.4 Gy 22.6 Attends regular school GH deficiency 
*Two individuals with <18 months of follow-up are excluded from this table 
)LJXUHD))3 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHD))3WLI
)LJXUHE26 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHE26WLI
)LJXUHD,7))3 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHD,7))3WLI
)LJXUHE,726 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHE,726WLI
)LJXUHF67))3 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHF67))3WLI
)LJXUHG6726 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHG6726WLI
)LJXUHHDOO))3 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHHDOO))3WLI
)LJXUHIDOO26 &OLFNKHUHWRDFFHVVGRZQORDG)LJXUH)LJXUHIDOO26WLI
Supplementary material 
Table e1. CSI dose by post-RT1 pattern of failure, with patient age at start of RT2 
CSI dose Distant failure Local failure Total 
 n Ages (y) n Ages (y)  
23.4 Gy 1 6.5 4 5.3-8.4 5 
36 Gy 8  3  11 
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Table e21. Individual patient details and vital status. 
Patient 
no. 
Primary 
site 
First 
surgery 
Subgroup Tumour 
grade 
Age at 
RT1 
(years) 
RT1 
dose 
(Gy) 
Systemic 
therapy at 
initial 
present-
ation 
Time to 
relapse 
from RT1 
(months) 
Site of 
relapse 
after 
RT1 
Surgery 
for initial 
relapse 
Age at 
RT2 
(years) 
 
RT2 dose 
(CSI 
dose/total 
dose) 
RT2 
type 
Relapse 
after 
RT2 
RT3 
details 
Last 
follow-up 
(months 
from 
RT2) 
Status 
1 
IT NTR 
PF-A 
3 13.0 54.0 none 15.3 local GTR 15.7 54.0 focal dissem 
SRS 21 
Gy 23.0 DOD 
2 
IT NTR 
n/a 
3 2.5 59.4 none 31.7 local GTR 5.4 54.0 focal dissem 
CSI 
23.4 
Gy + 
out-of-
field 
boost 
54 Gy 81.4 NED 
3 ST STR RELA 3 12.7 59.4 none 3.7 local GTR 13.2 36.0/54.0 CSI dissem  23.0 DOD 
4 IT NTR PF-A 3 2.8 59.4 yes 32.4 local GTR 5.8 54.0 focal local  36.7 DOD 
5 ST GTR n/a 3 10.3 54.0 none 9.8 local none 11.2 24.0 SRS   117.1 NED 
6 
ST NTR 
RELA 
3 8.9 59.4 yes 37.0 local NTR 12.1 54.0 focal local 
CSI 36 
Gy + 
in-field 
boost 
54 Gy 66.1 DOD 
7 IT NTR n/a 3 6.2 54.0 none 27.3 local none 8.6 15.0 SRS local  45.2 DOD* 
8 IT NTRSTR n/a 2 5.2 59.4 yes 16.3 local STR 7.1 54.0 focal local  53.1 DOD 
9 ST GTR RELA 2 10.6 54.0 none 138.3 local GTR 22.3 36.0/59.4 CSI   65.3 NED 
10 IT GTR PF-A 2 1.2 54.0 none 12.7 local GTR 2.4 54.0 focal dissem  28.4 DOD 
11 IT GTR PF-A 2 1.2 54.0 yes 23.6 local GTR 3.3 59.4 focal   81.6 NED 
12 
IT STR 
PF-A 
3 6.0 59.4 yes 13.5 local GTR 7.2 54.0 focal dissem 
whole 
spine 
36 Gy 
+ boost 
54 Gy 94.5 DOD 
13 IT GTR PF-A 2 1.8 54.0 none 40.5 local GTR 5.3 23.4/59.4 CSI   54.3 NED 
14 IT STR PF-A 2 2.8 59.4 yes 33.9 local** GTR 9.8 36.0/54.0 CSI   95.6 NED 
15 IT GTR PF-A 3 8.9 59.4 none 14.8 dissem NTR 10.2 36.0/54.0 CSI dissem  35.3 DOD 
16 IT GTR PF-A 3 11.4 59.4 none 19.4 dissem GTR 13.2 36.0/54.0 CSI   35.9 NED 
17 IT GTR PF-A 3 4.8 55.8 none 19.8 dissem biopsy 6.5 23.4/54.0 CSI dissem  25.4 DOD 
18 
IT NTR 
PF-A 
3 7.2 54.0 none 97.3 
local + 
dssem none 15.4 36.0/59.4 CSI  dissem 
focal 
54 Gy 22.7 DOD 
19 
ST NTR 
RELA 
3 6.2 59.4 none 12.2 
local + 
dissem none 7.3 36.0/54.0 CSI dissem  54.5 DOD 
20 IT GTR PF-A 3 7.4 59.4 yes 10.4 dissem GTR 8.3 36.0/54.0 CSI dissem  52.0 AWD 
21 
ST GTR 
RELA 
2 8.3 59.4 none 12.3 
local + 
dissem GTR 9.7 
36.0/ 
54.0 CSI  dissem 
whole 
spine 
28.8 
Gy + 
boost 
43.2 
Gy 18.4 DOD 
22 
IT NTR 
n/a 
 3 5.0 54.0 none 105.5 local GTR 15.0 54.0 focal dissem 
whole 
spine 
36 Gy 
+ boost 
54 Gy  29.6 DOD 
23 IT NTR PF-A 2 3.1 54.0 yes 8.5 local GTR 5.4 59.4 focal lung  64.4 AWD 
24 ST STR RELA 3 17.5 59.4 none 8.6 dissem GTR 18.4 36.0/54.0 CSI dissem  15.5 DOD 
25 IT STR n/a 2 2.7 54.0 none 19.0 local STR 4.6 59.4 focal local  11.8 DOD 
26 IT STR PF-A 2 2.9 54.0 yes 39.0 local GTR 6.6 54.0 focal   19.8 NED 
27 ST GTR n/a 3 7.1 59.4 none 14.0 local GTR 8.4 23.4/54.0 CSI   23.1 NED 
28 IT NTR PF-A 3 3.6 59.4 yes 29.4 local GTR 6.1 23.4/54.0 CSI   22.6 NED 
29 
ST STR 
n/a 
2 12.2 59.4 none 55.4 local STR 16.9 54.0 focal local 
focal 
51.2 
Gy 
56.9 
DOD 
30 IT GTR PF-A 3 9.7 59.4 none 20.7 dissem GTR 11.5 36.0/54.0 CSI   1.1 NED 
31 IT STR PF-A 2 5.1 59.4 yes 17.2 local STR 6.6 23.4/54.0 CSI   0.4 NED 
*Died in sleep with progressive ependymoma after RT2, but stable disease while on salvage chemotherapy (procarbazine, lomustine, vincristine). 
**Suspicious cerebrospinal fluid cytology prior to RT2, but no malignant cells and no radiological evidence of distant disease. 
 
AWD: alive with disease, CSI: craniospinal irradiation, dissem: disseminated, DOD: dead of disease, GTR: gross total resection, NED: no evidence of disease 
and alive, NTR: near total resection, IT: infratentorial (posterior fossa), n/a: not available; PF-A: posterior fossa group A; RT1: First course of radiotherapy, 
RT2: second course of radiotherapy, RT3: third course of radiotherapy, STR: subtotal resection, ST: supratentorial 
 
Figure e1. Re-irradiation for locally recurrent ependymoma 
a) 54 Gy focal RT2 for infratentorial local recurrence. Orange line represents PTV; solid 
orange represents modified PTV (a planning structure) to avoid brainstem, solid blue 
represents brainstem. 
b) 54 Gy boost to tumour bed for supratentorial isolated local relapse. Solid blue represents 
PTV. This treatment was preceded by c) 23.4 Gy craniospinal irradiation as part of RT2. 
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Figure e2. Outcomes for re-irradiated patients with local failure, by RT2 field and site of 
disease, excluding patients treated with SRS RT2: 
a) freedom-from-progression in patients with infratentorial primaries, b) overall survival in 
patients with infratentorial primaries; 
c) freedom-from-progression in patients with supratentorial primaries, d) overall survival in 
patients with supratentorial primaries; 
e) freedom-from-progression in all patients, f) overall survival in all patients 
 
Infratentorial primaries 
   
 
Supratentorial primaries 
  
 
All patients 
  
  
Details for patients who received three or more courses of radiotherapy (RT3) 
Following RT2, 8 patients went on to receive at least one more course of radiotherapy, with 
further overlap with previous fields in 7. Individual cases are discussed in detail below. 
 
Patient 1 developed disseminated supratentorial recurrence 2.5 months after focal 
infratentorial RT2 for local recurrence. The supratentorial recurrence was treated with 21 Gy 
single fraction SRS, 3.4 months after the RT2, to a region outside the previous two radiation 
fields (2 x 54.0 Gy to posterior fossa tumour bed), but in the low-dose region from both. 
Asymptomatic radiation necrosis developed 6 months following SRS; this was proactively 
treated with steroids. Local and disseminated recurrence occurred 19.4 months after SRS, 
with death shortly afterwards. 
 
Patient 2 relapsed with disseminated disease 15.8 months after focal infratentorial RT2 (59.4 
Gy RT1, then 54 Gy RT2), and was initially managed with systemic therapy but relapsed 
once more and so received surgery to the site of macroscopic dissemination and then CSI 23.4 
Gy to whole CNS and a boost to 54 Gy to the post-operative bed, 21.0 months after RT2. The 
RT3 boost was out-of-field to both RT1 and RT2. This patient remains alive 81 months after 
the RT1 and has no evidence of disease. 
 
Patient 6 received focal re-irradiation (59.4 Gy RT1, then 54 Gy RT2 to left frontal region) 
and developed focal relapse, 13.1 months after RT2. Systemic therapy and surgery were 
initially used, but at next progression, the patient received further surgery and CSI, 36 Gy to 
whole CNS, and an in-field boost to a total dose of 54 Gy at the local site of recurrence, 34.2 
months after RT2. Symptomatic radiation necrosis with right-sided weakness developed 7 
months after RT3, managed with steroids and hyperbaric oxygen (total physical dose to 
region: 59.4 Gy RT1 + 54.0 Gy RT2 + 54.0 Gy RT3 = 167.4 Gy). Symptoms improved with 
treatment, but the patient developed osteomyelitis of the skull flap requiring antibiotics. The 
patient ultimately developed further local relapse, 18.4 months after the RT3, and died 1 
month later.  
 
Patient 12 relapsed with disseminated disease in the spine 15.7 months after focal RT2 (59.4 
Gy RT1 to the infratentorial tumour bed, then 54Gy RT2 to the site of local failure). This 
individual was treated initially with systemic therapy, then surgery and spinal irradiation 
(RT3), 36 Gy in 20 fractions followed by 54 Gy to the site of macroscopic dissemination (not 
overlapping with previous fields), 20.6 months after RT2. Further relapse, this time 
supratentorially, developed 8.2 months after spinal irradiation (RT3); this was treated with 
surgery, then RT4, 36 Gy to the whole supratentorial brain, then a focal boost to 54 Gy to the 
post-operative bed. There was further relapse 10.1 months later, located at the site of original 
infratentorial disease, managed with 18 Gy frame-based stereotactic radiosurgery 40.9 months 
after the last posterior fossa irradiation (RT2). Further local relapse occurred here, 16.7 
months after SRS, managed with surgery alone. Further supratentorial relapse occurred 12.6 
months later, which was treated with systemic therapy. The patient has therefore received 114 
fractions of radiotherapy. Asymptomatic radionecrosis was observed 5 months after SRS (in a 
region irradiated on 3 occasions) but resolved without intervention. The patient died 94.5 
months after RT2, from progressive disease. 
 
Patient 18 received CSI as part of RT2 for disseminated (and local) relapse but developed 
further relapse a site of supratentorial macroscopic dissemination, 9.0 months after RT2 (RT1 
54 Gy to infratentorial tumour bed, followed by RT2 which consisted of 36 Gy CSI followed 
by boost RT2 to 59.4 Gy delivered to posterior fossa and supratentorial deposits). The 
disseminated lesion was managed with surgery, followed by 54 Gy in 30 fractions focal RT3, 
13.2 months after RT2. This patient developed further progression, out-of-field to RT3, and 
died 22.7 months after RT2. 
 
Patient 21 received CSI-RT2 for disseminated relapse. This individual initially had 59.4 Gy 
RT1 for a supratentorial primary, followed by RT2 which consisted of 36 Gy CSI followed by 
54.0 Gy boost the recurrent supratentorial tumour bed as well as spinal deposit tumour bed. 
The patient relapsed 10.3 months after RT2, with multiple spinal deposits which were in-field 
to the CSI-RT2 but out-of-field to the RT2 boost. Following near total resection, the patient 
received RT3, 13.5 months after the RT2, consisting of 28.8 Gy in 16 fractions to the whole 
spine, and boosts up to 43.2 Gy to the post-operative beds within the spine. Widespread intra-
cranial and spinal relapse occurred after 2.1 months, and the patient died 2 months later. 
 
Patient 22 initially had 54.0 Gy RT1, then 54.0 Gy RT2 to a recurrent posterior fossa tumour 
bed. 10.8 months after focal RT2, this patient relapsed with multiple spinal deposits. The 
patient received whole spine RT3, 10.6 months after RT1, 36 Gy in 20 fractions to whole 
CNS, with boosts up to 54 Gy to the areas of macroscopic disease within the spine.  After a 
further 6.6 months, there was further intracranial relapse for which the patient received RT4 
which consisted of 36 Gy in 20 fractions to the top of the posterior fossa and the entire 
supratentorial brain, followed by a 19.8 Gy in 11 fraction boost to the top of the posterior 
fossa. Five months after RT4, the patient received 20 Gy in 5 fractions (RT5) to the whole 
spine for recurrent spine disease. The patient died 5 months after RT5, or 29.6 months after 
RT2. 
 
Patient 29 received focal RT2 54.0 Gy (following 59.4 Gy RT1). This individual developed 
further local recurrence 33.5 months after RT2, which was initially managed with surgery and 
systemic therapy, followed by focal RT3 51.2 Gy in 32 fractions, which was delivered 51.7 
months after the RT2. The patient relapsed with disseminated disease 2.9 months after RT3; 
this was managed with best supportive care. The patient died 2 months later.  
 
Supplementary material 
Table e1. CSI dose by post-RT1 pattern of failure, with patient age at start of RT2 
CSI dose Distant failure Local failure Total 
 n Ages (y) n Ages (y)  
23.4 Gy 1 6.5 4 5.3-8.4 5 
36 Gy 8  3  11 
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 Table e2. Individual patient details and vital status. 
Patient 
no. 
Primary 
site 
First 
surgery 
Subgroup Tumour 
grade 
Age at 
RT1 
(years) 
RT1 
dose 
(Gy) 
Systemic 
therapy at 
initial 
present-
ation 
Time to 
relapse 
from RT1 
(months) 
Site of 
relapse 
after 
RT1 
Surgery 
for initial 
relapse 
Age at 
RT2 
(years) 
 
RT2 dose 
(CSI 
dose/total 
dose) 
RT2 
type 
Relapse 
after 
RT2 
RT3 
details 
Last 
follow-up 
(months 
from 
RT2) 
Status 
1 
IT NTR 
PF-A 
3 13.0 54.0 none 15.3 local GTR 15.7 54.0 focal dissem 
SRS 21 
Gy 23.0 DOD 
2 
IT NTR 
n/a 
3 2.5 59.4 none 31.7 local GTR 5.4 54.0 focal dissem 
CSI 
23.4 Gy 
+ out-
of-field 
boost 
54 Gy 81.4 NED 
3 ST STR RELA 3 12.7 59.4 none 3.7 local GTR 13.2 36.0/54.0 CSI dissem  23.0 DOD 
4 IT NTR PF-A 3 2.8 59.4 yes 32.4 local GTR 5.8 54.0 focal local  36.7 DOD 
5 ST GTR n/a 3 10.3 54.0 none 9.8 local none 11.2 24.0 SRS   117.1 NED 
6 
ST NTR 
RELA 
3 8.9 59.4 yes 37.0 local NTR 12.1 54.0 focal local 
CSI 36 
Gy + in-
field 66.1 DOD 
boost 
54 Gy 
7 IT NTR n/a 3 6.2 54.0 none 27.3 local none 8.6 15.0 SRS local  45.2 DOD* 
8 IT STR n/a 2 5.2 59.4 yes 16.3 local STR 7.1 54.0 focal local  53.1 DOD 
9 ST GTR RELA 2 10.6 54.0 none 138.3 local GTR 22.3 36.0/59.4 CSI   65.3 NED 
10 IT GTR PF-A 2 1.2 54.0 none 12.7 local GTR 2.4 54.0 focal dissem  28.4 DOD 
11 IT GTR PF-A 2 1.2 54.0 yes 23.6 local GTR 3.3 59.4 focal   81.6 NED 
12 
IT STR 
PF-A 
3 6.0 59.4 yes 13.5 local GTR 7.2 54.0 focal dissem 
whole 
spine 
36 Gy + 
boost 
54 Gy 94.5 DOD 
13 IT GTR PF-A 2 1.8 54.0 none 40.5 local GTR 5.3 23.4/59.4 CSI   54.3 NED 
14 IT STR PF-A 2 2.8 59.4 yes 33.9 local** GTR 9.8 36.0/54.0 CSI   95.6 NED 
15 IT GTR PF-A 3 8.9 59.4 none 14.8 dissem NTR 10.2 36.0/54.0 CSI dissem  35.3 DOD 
16 IT GTR PF-A 3 11.4 59.4 none 19.4 dissem GTR 13.2 36.0/54.0 CSI   35.9 NED 
17 IT GTR PF-A 3 4.8 55.8 none 19.8 dissem biopsy 6.5 23.4/54.0 CSI dissem  25.4 DOD 
18 
IT NTR 
PF-A 
3 7.2 54.0 none 97.3 
local + 
dssem none 15.4 36.0/59.4 CSI  dissem 
focal 54 
Gy 22.7 DOD 
19 
ST NTR 
RELA 
3 6.2 59.4 none 12.2 
local + 
dissem none 7.3 36.0/54.0 CSI dissem  54.5 DOD 
20 IT GTR PF-A 3 7.4 59.4 yes 10.4 dissem GTR 8.3 36.0/54.0 CSI dissem  52.0 AWD 
21 
ST GTR 
RELA 
2 8.3 59.4 none 12.3 
local + 
dissem GTR 9.7 
36.0/ 
54.0 CSI  dissem 
whole 
spine 
28.8 Gy 
+ boost 
43.2 Gy 18.4 DOD 
22 
IT NTR 
n/a 
 3 5.0 54.0 none 105.5 local GTR 15.0 54.0 focal dissem 
whole 
spine 
36 Gy + 
boost 
54 Gy  29.6 DOD 
23 IT NTR PF-A 2 3.1 54.0 yes 8.5 local GTR 5.4 59.4 focal lung  64.4 AWD 
24 ST STR RELA 3 17.5 59.4 none 8.6 dissem GTR 18.4 36.0/54.0 CSI dissem  15.5 DOD 
25 IT STR n/a 2 2.7 54.0 none 19.0 local STR 4.6 59.4 focal local  11.8 DOD 
26 IT STR PF-A 2 2.9 54.0 yes 39.0 local GTR 6.6 54.0 focal   19.8 NED 
27 ST GTR n/a 3 7.1 59.4 none 14.0 local GTR 8.4 23.4/54.0 CSI   23.1 NED 
28 IT NTR PF-A 3 3.6 59.4 yes 29.4 local GTR 6.1 23.4/54.0 CSI   22.6 NED 
29 
ST STR 
n/a 
2 12.2 59.4 none 55.4 local STR 16.9 54.0 focal local 
focal 
51.2 Gy 
56.9 
DOD 
30 IT GTR PF-A 3 9.7 59.4 none 20.7 dissem GTR 11.5 36.0/54.0 CSI   1.1 NED 
31 IT STR PF-A 2 5.1 59.4 yes 17.2 local STR 6.6 23.4/54.0 CSI   0.4 NED 
*Died in sleep with progressive ependymoma after RT2, but stable disease while on salvage chemotherapy (procarbazine, lomustine, vincristine). 
**Suspicious cerebrospinal fluid cytology prior to RT2, but no malignant cells and no radiological evidence of distant disease. 
 AWD: alive with disease, CSI: craniospinal irradiation, dissem: disseminated, DOD: dead of disease, GTR: gross total resection, NED: no evidence of disease 
and alive, NTR: near total resection, IT: infratentorial (posterior fossa), n/a: not available; PF-A: posterior fossa group A; RT1: First course of radiotherapy, 
RT2: second course of radiotherapy, RT3: third course of radiotherapy, STR: subtotal resection, ST: supratentorial 
 
Figure e1. Re-irradiation for locally recurrent ependymoma 
a) 54 Gy focal RT2 for infratentorial local recurrence. Orange line represents PTV; solid 
orange represents modified PTV (a planning structure) to avoid brainstem, solid blue 
represents brainstem. 
b) 54 Gy boost to tumour bed for supratentorial isolated local relapse. Solid blue represents 
PTV. This treatment was preceded by c) 23.4 Gy craniospinal irradiation as part of RT2. 
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Figure e2. Outcomes for re-irradiated patients with local failure, by RT2 field and site of 
disease, excluding patients treated with SRS RT2: 
a) freedom-from-progression in patients with infratentorial primaries, b) overall survival in 
patients with infratentorial primaries; 
c) freedom-from-progression in patients with supratentorial primaries, d) overall survival in 
patients with supratentorial primaries; 
e) freedom-from-progression in all patients, f) overall survival in all patients 
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Details for patients who received three or more courses of radiotherapy (RT3) 
Following RT2, 8 patients went on to receive at least one more course of radiotherapy, with 
further overlap with previous fields in 7. Individual cases are discussed in detail below. 
 
Patient 1 developed disseminated supratentorial recurrence 2.5 months after focal 
infratentorial RT2 for local recurrence. The supratentorial recurrence was treated with 21 Gy 
single fraction SRS, 3.4 months after the RT2, to a region outside the previous two radiation 
fields (2 x 54.0 Gy to posterior fossa tumour bed), but in the low-dose region from both. 
Asymptomatic radiation necrosis developed 6 months following SRS; this was proactively 
treated with steroids. Local and disseminated recurrence occurred 19.4 months after SRS, 
with death shortly afterwards. 
 
Patient 2 relapsed with disseminated disease 15.8 months after focal infratentorial RT2 (59.4 
Gy RT1, then 54 Gy RT2), and was initially managed with systemic therapy but relapsed 
once more and so received surgery to the site of macroscopic dissemination and then CSI 23.4 
Gy to whole CNS and a boost to 54 Gy to the post-operative bed, 21.0 months after RT2. The 
RT3 boost was out-of-field to both RT1 and RT2. This patient remains alive 81 months after 
the RT1 and has no evidence of disease. 
 
Patient 6 received focal re-irradiation (59.4 Gy RT1, then 54 Gy RT2 to left frontal region) 
and developed focal relapse, 13.1 months after RT2. Systemic therapy and surgery were 
initially used, but at next progression, the patient received further surgery and CSI, 36 Gy to 
whole CNS, and an in-field boost to a total dose of 54 Gy at the local site of recurrence, 34.2 
months after RT2. Symptomatic radiation necrosis with right-sided weakness developed 7 
months after RT3, managed with steroids and hyperbaric oxygen (total physical dose to 
region: 59.4 Gy RT1 + 54.0 Gy RT2 + 54.0 Gy RT3 = 167.4 Gy). Symptoms improved with 
treatment, but the patient developed osteomyelitis of the skull flap requiring antibiotics. The 
patient ultimately developed further local relapse, 18.4 months after the RT3, and died 1 
month later.  
 
Patient 12 relapsed with disseminated disease in the spine 15.7 months after focal RT2 (59.4 
Gy RT1 to the infratentorial tumour bed, then 54Gy RT2 to the site of local failure). This 
individual was treated initially with systemic therapy, then surgery and spinal irradiation 
(RT3), 36 Gy in 20 fractions followed by 54 Gy to the site of macroscopic dissemination (not 
overlapping with previous fields), 20.6 months after RT2. Further relapse, this time 
supratentorially, developed 8.2 months after spinal irradiation (RT3); this was treated with 
surgery, then RT4, 36 Gy to the whole supratentorial brain, then a focal boost to 54 Gy to the 
post-operative bed. There was further relapse 10.1 months later, located at the site of original 
infratentorial disease, managed with 18 Gy frame-based stereotactic radiosurgery 40.9 months 
after the last posterior fossa irradiation (RT2). Further local relapse occurred here, 16.7 
months after SRS, managed with surgery alone. Further supratentorial relapse occurred 12.6 
months later, which was treated with systemic therapy. The patient has therefore received 114 
fractions of radiotherapy. Asymptomatic radionecrosis was observed 5 months after SRS (in a 
region irradiated on 3 occasions) but resolved without intervention. The patient died 94.5 
months after RT2, from progressive disease. 
 
Patient 18 received CSI as part of RT2 for disseminated (and local) relapse but developed 
further relapse a site of supratentorial macroscopic dissemination, 9.0 months after RT2 (RT1 
54 Gy to infratentorial tumour bed, followed by RT2 which consisted of 36 Gy CSI followed 
by boost RT2 to 59.4 Gy delivered to posterior fossa and supratentorial deposits). The 
disseminated lesion was managed with surgery, followed by 54 Gy in 30 fractions focal RT3, 
13.2 months after RT2. This patient developed further progression, out-of-field to RT3, and 
died 22.7 months after RT2. 
 
Patient 21 received CSI-RT2 for disseminated relapse. This individual initially had 59.4 Gy 
RT1 for a supratentorial primary, followed by RT2 which consisted of 36 Gy CSI followed by 
54.0 Gy boost the recurrent supratentorial tumour bed as well as spinal deposit tumour bed. 
The patient relapsed 10.3 months after RT2, with multiple spinal deposits which were in-field 
to the CSI-RT2 but out-of-field to the RT2 boost. Following near total resection, the patient 
received RT3, 13.5 months after the RT2, consisting of 28.8 Gy in 16 fractions to the whole 
spine, and boosts up to 43.2 Gy to the post-operative beds within the spine. Widespread intra-
cranial and spinal relapse occurred after 2.1 months, and the patient died 2 months later. 
 
Patient 22 initially had 54.0 Gy RT1, then 54.0 Gy RT2 to a recurrent posterior fossa tumour 
bed. 10.8 months after focal RT2, this patient relapsed with multiple spinal deposits. The 
patient received whole spine RT3, 10.6 months after RT1, 36 Gy in 20 fractions to whole 
CNS, with boosts up to 54 Gy to the areas of macroscopic disease within the spine.  After a 
further 6.6 months, there was further intracranial relapse for which the patient received RT4 
which consisted of 36 Gy in 20 fractions to the top of the posterior fossa and the entire 
supratentorial brain, followed by a 19.8 Gy in 11 fraction boost to the top of the posterior 
fossa. Five months after RT4, the patient received 20 Gy in 5 fractions (RT5) to the whole 
spine for recurrent spine disease. The patient died 5 months after RT5, or 29.6 months after 
RT2. 
 
Patient 29 received focal RT2 54.0 Gy (following 59.4 Gy RT1). This individual developed 
further local recurrence 33.5 months after RT2, which was initially managed with surgery and 
systemic therapy, followed by focal RT3 51.2 Gy in 32 fractions, which was delivered 51.7 
months after the RT2. The patient relapsed with disseminated disease 2.9 months after RT3; 
this was managed with best supportive care. The patient died 2 months later.  
 
